Skip to main content
American Journal of Physiology - Heart and Circulatory Physiology logoLink to American Journal of Physiology - Heart and Circulatory Physiology
. 2013 Apr 12;304(12):H1598–H1614. doi: 10.1152/ajpheart.00490.2012

The effects of hypertension on the cerebral circulation

Paulo W Pires 1, Carla M Dams Ramos 1, Nusrat Matin 1, Anne M Dorrance 1,
PMCID: PMC4280158  PMID: 23585139

Abstract

Maintenance of brain function depends on a constant blood supply. Deficits in cerebral blood flow are linked to cognitive decline, and they have detrimental effects on the outcome of ischemia. Hypertension causes alterations in cerebral artery structure and function that can impair blood flow, particularly during an ischemic insult or during periods of low arterial pressure. This review will focus on the historical discoveries, novel developments, and knowledge gaps in 1) hypertensive cerebral artery remodeling, 2) vascular function with emphasis on myogenic reactivity and endothelium-dependent dilation, and 3) blood-brain barrier function. Hypertensive artery remodeling results in reduction in the lumen diameter and an increase in the wall-to-lumen ratio in most cerebral arteries; this is linked to reduced blood flow postischemia and increased ischemic damage. Many factors that are increased in hypertension stimulate remodeling; these include the renin-angiotensin-aldosterone system and reactive oxygen species levels. Endothelial function, vital for endothelium-mediated dilation and regulation of myogenic reactivity, is impaired in hypertension. This is a consequence of alterations in vasodilator mechanisms involving nitric oxide, epoxyeicosatrienoic acids, and ion channels, including calcium-activated potassium channels and transient receptor potential vanilloid channel 4. Hypertension causes blood-brain barrier breakdown by mechanisms involving inflammation, oxidative stress, and vasoactive circulating molecules. This exposes neurons to cytotoxic molecules, leading to neuronal loss, cognitive decline, and impaired recovery from ischemia. As the population ages and the incidence of hypertension, stroke, and dementia increases, it is imperative that we gain a better understanding of the control of cerebral artery function in health and disease.

Keywords: artery remodeling, cerebral vasculature, hypertension


this article is part of a collection on Unique Features of Cerebral Circulation. Other articles appearing in this collection, as well as a full archive of all collections, can be found online at http://ajpheart.physiology.org/.

The brain is one of the most highly perfused organs in the body. Yet our knowledge and understanding of this vascular bed in health and disease lags behind that of the peripheral circulation. The cerebral vasculature has several unique features that require it to be considered separately from other vascular beds (30, 50, 67). For example, the large cerebral arteries contribute significantly to the cerebral vascular resistance and therefore contribute to the regulation of cerebral blood flow (70). Also, the cells making up the vessels interact with a diverse array of other cell types including neurons, astrocytes, pericytes, and glial cells. Finally, the presence of the blood-brain barrier (BBB) at the level of the endothelium confers unique properties on the cerebral circulation (2). Many studies have focused on the effects of hypertension on the cerebral arteries. These studies are of paramount importance because hypertension is a major risk factor for stroke (110, 120), which is a leading cause of death in the United States. Hypertension has also been implicated in vascular cognitive impairment (183) and Alzheimer's disease (109, 185), and both of these conditions have a significant vascular pathology. The purpose of this review is to highlight recent developments in the study of the effects of hypertension on the cerebral circulation. This review will focus on three aspects of the cerebral circulation: 1) artery structure, 2) artery reactivity, and 3) BBB function. These subject areas were selected because significant knowledge gaps exist in each. Table 1 contains the definitions of commonly used terms in the field.

Table 1.

List of definitions used in this review

Autoregulation The ability of the cerebral vasculature to respond to changes in perfusion pressure in a manner that maintains cerebral blood flow contstant.
Calcium spark Transient and localized increase in intracellular Ca2+ caused by opening of ryanodine receptor in the sarcoplasmic reticulum.
Calcium sparklet Small and transient calcium influx caused by opening of a single or very few calcium permeable channels in the plasma membrane.
Collateral circulation The subsidiary network of small arteries that maintain blood flow to the parenchyma when flow through a major artery is impaired.
Force-mediated dilation Complete loss of myogenic tone that occurs at intralumenal pressures above the upper end of the autoregulatory range of the artery.
Functional hyperemia Local and transient increases in cerebral blood flow to match immediate neuronal metabolic demand.
Growth Alterations in wall cross-sectional area of arteries. It can be classified as “hypertrophic” (increase in the wall cross-sectional area), “hypotrophic” (reduction in wall cross-sectional area), or “eutrophic” (no changes in cross-sectional area despite a change in the lumen diameter).
Myogenic reactivity Ability of the artery to change its tone to respond to fluctuations in intralumenal pressure while keeping blood flow relatively constant.
Myogenic tone Intrinsic property of arteries and arterioles to spontaneously maintain active contractile force in the smooth muscle cells of the vascular wall. Multiple factors contribute to the regulation of myogenic tone. These include the pressure inside the vessel, the resting potassium conductance, calcium channel activity, and the sensitivity of the contractile signaling pathways to calcium. Factors extrinsic to the smooth muscle, hypoxia, for example, also regulate tone.
Neurovascular unit Structure formed by endothelial cells encased within a basal lamina and surrounded by pericytes and astrocytic end-feet that generates the bulk of the blood-brain barrier.
Passive vascular structure For the purpose of this review, we classified passive structure as any measurement of vascular structure made when the vessels are maximally relaxed because Ca2+ is not present in the environment (Ca2+-free buffers and chelators).
Vascular remodeling Alterations in the structure of blood vessels observed in chronic hypertension. It can be classified as “inward” (reduction in vessel cross-sectional area) or “outward” (increase in vessel cross-sectional area).

Cerebral Vessel Anatomy

The anatomy of the cerebral circulation was recently eloquently described in detail (30); therefore, discussion here will be limited to the intracranial arteries frequently studied in hypertension. The basilar artery, which arises from the vertebral arteries, runs along the midline of the brain stem and connects with the circle of Willis, an anastomotic ring that allows for cross perfusion of the cerebral hemispheres. Three large arteries branch off of the circle of Willis; these are the posterior, anterior, and middle cerebral arteries, with the latter being the best studied (Fig. 1A). These large cerebral arteries branch into the pial or leptomeningeal arteries, which form a collateral network that allows cerebral blood flow to circumvent an occlusion. In fact, this is one of the first areas identified as having cerebrovascular dysfunction because of hypertension; the pial collateral arteries from stroke-prone spontaneously hypertensive rats (SHRSP) have an impaired ability to dilate in response to an ischemic insult compared with the same vessels in normotensive rats (41). This is thought to contribute to the large infarct observed after middle cerebral artery (MCA) occlusion in SHRSP (43). The large cerebral and pial arteries carry a significant amount of the vascular resistance, making them important regulators of cerebral blood flow (30, 70). Interestingly, the contribution of the different segments of the vascular bed to cerebrovascular resistance changes as hypertension develops in spontaneously hypertensive rats (SHR). In the established phase of hypertension, the small arteries and arterioles carry more of the vascular resistance than they do in young rats with developing hypertension (18). Most studies of the effects of hypertension on cerebral arteries have been conducted in young, albeit hypertensive, rats. Because the control of vascular resistance changes with the duration of hypertension, studying older hypertensive rats may yield a different, and perhaps more clinically relevant, picture of the vascular response to hypertension.

Fig. 1.

Fig. 1.

A: large cerebral arteries and the circle of Willis. B: cross-sectional representation of a segment of the cerebral circulation including the perivascular nerves. Extrinsic innervation of the vessels at the surface of the brain comes from the peripheral nervous system (PNS), nerves originate in the superior cervical (SCG), sphenopalatine (SPG), or otic (OG) or trigeminal (TG) ganglion. Arteries within the brain parenchyma, or the microcirculation, receive intrinsic inniveration; these nerves originate in the central nervous system (CNS). Cortical microvessels receive norepinephrine (NA), serotonin (5-HT), acetylcholine (ACh), or GABAergic afferents from subcortical neurons from the locus coeruleus, raphe nucleus, basal forebrain, or local cortical interneurons. Inset: neurovascular unit, which consists of the vascular endothelium, and smooth muscle cells or pericytes, astroglia, and neurons. CGRP, calcitonin gene-related peptide; GABA, γ-aminobutyric acid; NKA, neurokinin A; NOS, nitric oxide (NO) synthase; NPY, neuropeptide Y; PACAP, pituitary adenylate-cyclase activating polypeptide; SOM, somatostatin; SP, substance P; VIP, vasoactive intestinal polypeptide. Reproduced from Hamel (83) with permission.

The penetrating and parenchymal arterioles enter the brain and perfuse the parenchyma (Fig. 1B). The penetrating arterioles are located in the Virchow-Robin space and are bathed with cerebrospinal fluid. The penetrating arterioles connect pial vasculature with the parenchymal arteriole capillary beds that perfuse the brain parenchyma. Unlike the surface arteries and pial arterioles, the penetrating arterioles have very few anastomoses (139). Thus the penetrating arterioles control the blood flow to very discrete regions of the cortex and act as a bottleneck to blood flow between the surface of the brain and the capillary bed (152). The parenchymal arterioles are, as their name suggests, located in the parenchyma surrounded by astrocytic end feet (37). Little is known about how hypertension affects these arteries (16, 23, 113).

The parenchymal arterioles give rise to capillaries. Capillary endothelial cells are surrounded by pericytes, and these two cell types are encased in the basal lamina. The astrocytic end feet abut against this basal lamina, and these three cell types, along with adjacent neurons, make up the neurovascular unit, a region of the cerebral vasculature that has garnered a huge amount of interest recently, largely because it has been viewed as a potential therapeutic target for ischemic strokes (50). Capillary endothelial cells are commonly used to study BBB function. It is important to note that the barrier properties of the cerebral circulation are not limited to the capillaries; the large arteries and arterioles also contribute (30, 149).

There are stark differences in the innervation of the cerebral blood vessels depending on their location in the brain (Fig. 1B). The pial arteries receive extrinsic innervation from the peripheral nervous system. The nerves involved mostly arise from the superior cervical ganglion, although some fibers arise from the sphenopalatine, otic, and trigeminal ganglia. These nerves form a network of varicose fibers within the adventitia of the arteries. The density of these fibers begins to fall as the arteries enter the Virchow-Robin space, and they are not present in the parenchymal arterioles (83). The parenchymal arterioles receive intrinsic innervation from within the neuropil. Cortical microvessels receive noradrenergic, serotonergic, cholinergic, or GABAergic afferents from subcortical neurons from the locus coeruleus, raphe nucleus, basal forebrain, or local cortical interneurons (83), although the nerves associated with the vessels mostly target the astrocytes around the blood vessels (38). Similarly the postjunctional receptors for neurotransmitters vary within the vascular tree. For example, norepinephrine causes submaximal contraction in the MCA through activation of the α1-adrenoreceptors (57, 92), but β-adrenoreceptors predominate in the parenchymal arterioles and they elicit dilation in response to norepinephrine. Similar heterogeneous expression exists for the serotonin receptors (121).

Hypertension-Associated Changes in The Structure of the Cerebral Vasculature

An increase in peripheral vascular resistance is a hallmark of hypertension. Vascular resistance can be increased by reducing the lumen diameter or the number of arteries or by increasing the length of arteries. There is ample evidence in the literature to suggest that hypertension reduces both the lumen diameter and the vessel number in the cerebral vasculature.

Vessel Rarefaction

Rarefaction or loss of arterioles and capillaries has been reported for several models of hypertension although the effects are not uniform across vessel types or models of hypertension. One of the most extensive studies conducted in this area was performed by Sokolova et al. (188) using several models of hypertension including renal wrap, deoxycorticosterone acetate (DOCA)-salt, and SHR. In renal wrap and DOCA-salt hypertensive rats, there was a 25–50% reduction in the number of pial arteries and intracerebral capillaries (inner diameter = 1.4–5.6 μm). A reduction in the capillary number was also observed in the SHR (188). The authors did not report the effects of hypertension on pial artery numbers in SHR, but others have confirmed a reduced capillary density in these rats. In this case, the reduction in capillary density was likely blood pressure dependent as it did not occur in young SHR but had developed in 12-wk-old rats with marked hypertension (162). Other studies have shown similar vessel rarefaction in rats with 2-kidney 2-clip (2K2C) hypertension (194).

Whereas hypertension reduces the number of intracerebral capillaries, the same cannot be said for the pial arteries where the effects of hypertension are more controversial, particularly in genetic models of hypertension. Coyle and Heistad (42) showed that the number of pial collateral vessels between the MCA and the anterior cerebral artery is the same in SHRSP and normotensive rats (42). This finding was confirmed by others using SHR (87), Goldblatt, DOCA-salt, and Dahl salt-sensitive rats (208). However, the pial artery rarefaction noted in the study by Sokolova et al. (188) was in models of secondary hypertension including the DOCA-salt and renal-wrap hypertensive rats. The reason for these disparate findings is not clear and cannot be attributed to the duration or magnitude of the hypertension as the rats used by Sokolova et al. had lower blood pressure and had been hypertensive for a shorter period of time than the rats without pial artery rarefaction (208).

Arteriole and capillary loss could lead to a reduction in cerebral blood flow, which could in turn cause chronic hypoperfusion of the brain. Although this has not been directly studied in hypertension, studies in a mouse model of cerebral small vessel disease suggest this is a possibility. In mice with small vessel disease, capillary loss in the white matter was observed before a significant reduction in cerebral blood flow and white matter injury was observed (107). Capillary loss may be the mechanism responsible for the increased risk of vascular cognitive impairment or vascular dementia in patients with hypertension (47). However, to the best of our knowledge there are no studies documenting cerebral artery rarefaction in hypertensive patients. Several unknowns remain. For example, it is not clear whether intervention in hypertensive rats reduces rarefaction or whether vessel loss can be reversed. Hopefully, the increasing use of advanced imaging techniques will answer these questions in a definitive manner.

Artery Remodeling and Hypertrophy

Hypertension results in changes in the structure of the arteries that makes them different from those of a normotensive animal or patient. The terminology to describe these structural changes has developed over a number of years. Initially, the term remodeling was used to describe a reduced lumen diameter and increased wall-to-lumen ratio (13). Remodeling can be described as inward or outward, depending on how the lumen diameter changes. Later modifications to the term remodeling took into account the fact that growth is not always part of the remodeling process. The term eutrophic remodeling is used to indicate a change in media-to-lumen or wall-to-lumen ratio without a difference in the wall cross-sectional area. Hypertrophic remodeling occurs when the wall area is increased, and hypotrophic remodeling describes a reduced wall area along with reduced wall-to-lumen ratio (146). Artery remodeling can be quantified using the remodeling index, which is the percent change in lumen diameter attributed to eutrophic remodeling, and the growth index, which is the percent change in the cross-sectional area (13, 89). Although these indexes provide important information, they are not frequently reported in the literature.

Studies to define the type of remodeling in a given vascular bed should be conducted on fully relaxed vessels. Most commonly, these studies are conducted using calcium-free solutions; some researchers also include calcium chelators and vasodilators. For the purpose of this review, measures made under these conditions will be described as the passive structure of the arteries. It is important to note that under physiological conditions, the ability of arteries to contract and dilate adds another layer to the regulation of blood flow that cannot be accounted for in studies of passive structure.

The passive structure of arteries is particularly important in situations like cerebral ischemia where the vessels around the occlusion become maximally dilated. In this situation, small changes in passive lumen diameter will dramatically affect blood flow. The increased wall-to-lumen ratio observed in arteries from hypertensive rats is generally thought to cause an increase in the vascular response to constrictor agents (145, 147, 199). However, several lines of evidence suggest that in the large cerebral arteries from SHRSP, the contractile response is reduced despite an increase in the wall-to-lumen ratio (3, 5, 201). This unexpected finding suggests that smooth muscle cells (SMCs) in cerebral arteries from hypertensive rats may compensate for artery remodeling by decreasing their responsiveness to constrictor agents.

The change in artery structure that occurs with hypertension is one of the better-studied aspects of the cerebral circulation. Folkow et al (72) first proposed in 1973 that a reduction in the lumen diameter of arteries increases vascular resistance. A recent review by Mulvany (144) highlighted the importance of vascular remodeling in the pathogenesis of hypertension. The effects of hypertension on artery structure have been reviewed in the past (9, 89, 91), and we have compiled some of the key historical findings along with more recent studies in Table 2. Although this is not an exhaustive list, it is a representative list of major findings in the field.

Table 2.

A summary of the effects of hypertension on the cerebral arteries

Model Treatment Compared With Arteries Studied Wall Thickness Wall Area Lumen Diameter Wall-to-lumen ratio Blood Pressure Method Used
SHRSP WKY Pial Cranial window (13)*
SHRSP Cilazapril Placebo-treated SHRSP Pial Cranial window (82)
Hydralazine = =
SHRSP Bosentan Placebo-treated SHRSP Pial Cranial window (29)
SHRSP Perindopril Placebo-treated SHRSP Pial = Cranial Window (26)*
Propanolol
Perindopril + propanolol =
SHRSP Tempol Placebo-treated SHRSP MCA = = = = Pressure myograph (167)
SHRSP Spironolactone Untreated SHRSP MCA = = = Pressure myograph (174)
SHRSP Spironolactone Untreated SHRSP MCA = = Pressure myograph (173)
SHRSP Doxycycline Untreated SHRSP MCA Pressure myograph (168)
SHRSP SHR MCA Pressure myograph (101)*
SHRSP High-salt diet Control diet-fed SHRSP Basilar Wire myograph (3)
Lacidipine + high-salt diet
SHR WKY Pial Cranial window (11)*
SHR Indapamide Placebo-treated SHR Pial = Cranial window (28)
SHRs Telmisartan Placebo-treated SHR MCA = = Histology (116)
Basilar
l-NAME (WKY) Control WKY Basilar = Pressure myograph (140)
Verapamil l-NAME + placebo-treated rats = = = =
Trandolapril = =
l-NAME (SD) Rosiglitazone l-NAME + placebo-treated rats PCA Pressure myograph (31)
DOCA-salt Pial Histology (188)
GH rats Valsartan Placebo-treated GH rats Basilar Histology (118)
Simvastatin = = =
Simvastatin + valsartan
Enalapril
Simvastatin + enalapril =
RH rat Normotensive rats Pial = = Cranial window (11)
*

Seminal finding in the field. SHRSP, stroke-prone spontaneously hypertensive rats (SHR); WKY, Wistar-Kyoto rats; SD, Sprague Dawley rats; l-NAME, NG-nitro-l-arginine methyl ester; GH, New Zealand genetically hypertensive rats; RH, renal hypertensive rats; DOCA-salt, deoxycorticosterone acetate salt-treated rats; MCA, middle cerebral artery; PCA, posterior cerebral artery.

Cerebral artery hypertrophy and remodeling are adaptive processes that reduce the stress on the artery wall and protect the arterioles and downstream capillaries and venules from increased blood pressure (12, 117). Failure of the cerebral arteries to remodel in response to increased blood pressure has detrimental effects including vasogenic edema and BBB breakdown (95).

Hypertension increases the tangential stress on the artery wall (88). To maintain this stress within a physiological range in the face of elevated intralumenal pressure, artery wall thickness increases. In cerebral arteries this is generally associated with a reduction in the lumen diameter (89, 143) and an increase in the wall-to-lumen ratio. The latter is an important prognosticator of end-organ damage (102) and cardiovascular events such as stroke or myocardial infarction (46). The effects of hypertension on the area of the artery wall have been more difficult to define. This might be because in studies using pressurized arteries or cranial windows, this is often a derived variable, compounding experimental errors, making statistical significance more difficult to achieve. Clarifying the effect of hypertension on the wall area could help define the mechanisms responsible for artery remodeling.

Generally, in models of essential hypertension, such as the SHR and SHRSP, the large vessels like the MCA (52, 174) and pial arteries (13) have smaller lumens and thicker walls. The same can be said for the MCAs from rats with obesity-induced hypertension (49, 157), mineralocorticoid receptor-dependent hypertension (54, 156), and NG-nitro-l-arginine methyl ester (l-NAME)-dependent hypertension (140). A reduction in the lumen diameter of pial arteries has also been observed in DOCA-salt hypertensive rats (188). Interestingly, in renal hypertension, the pial arterioles have a normal lumen diameter, but the wall thickness is increased, and although not measured, this should increase the wall-to-lumen ratio (11). These studies highlight the fact that blood pressure alone is not the sole stimulus for the reduced lumen diameter found in many models of hypertension. In fact, the blood pressure independency of the remodeling process has proven to be a fruitful area of research as discussed below.

In SHRSP, pial artery remodeling develops as the rats age. In 3- to 4-mo-old SHRSP, the passive lumen diameter of the pial arteries is not reduced, but by 10–12 mo of age, there is a marked inward remodeling of these arteries compared with arteries from normotensive Wistar-Kyoto (WKY) rats (10, 13). It is important to note that at 3 mo of age, SHRSP are markedly hypertensive (45), so the pial arteries maintain a normal structure for some time even in the presence of elevated blood pressure. The MCAs from SHRSP have smaller lumens and an increased wall-to-lumen ratio, and this remodeling develops earlier than it does in the pial arteries (52, 168, 174). As with rarefaction, this suggests that various segments of the vascular bed remodel differently in response to hypertension. The progression of remodeling down the arterial tree to the smaller vessels over time is in keeping with the studies showing that vascular resistance increases in the smaller vessels in the sustained phase of the hypertension (18).

The structural alterations in cerebral arteries from SHRSP are accompanied by alterations in the SMC organization in the artery wall. Under normal conditions, the SMCs are arranged circularly around the artery wall. Using confocal microscopy to image pressurized basilar arteries from SHRSP, Arribas et al. (3, 5) showed a disorganization of the SMCs in the medial layer compared with arteries from normotensive WKY rats. In the SHRSP, many of the SMCs were orientated such that their long axis was no longer at a 90° angle to the direction of blood flow (3, 5). These misaligned cells were in discrete areas of the vessel wall, and were associated with a reduced thickness of the advential layer. The authors present the interesting idea that these areas are points of weakness in the artery that could increase the risk of hemorrhage in SHRSP (3). The changes in the organization of the medial layer were associated with impaired contraction to potassium chloride. The same group of researchers also studied rats with experimental hypertension induced by nitric oxide (NO) synthase inhibition with l-NAME. Whereas artery remodeling was observed in these rats, the authors did not observe the same disorganization of the SMCs (4). It is therefore possible that this cell reorientation is a genetic trait particular to the SHRSP. However, it is also possible that the duration or magnitude of the hypertension contributes to the disparity in the results since the rats were only treated with l-NAME for 3 wk, whereas the SHRSP were 14 wk old when they were studied and would have had significant hypertension for at least 6 wk (45).

Effects of the Renin-Angiotensin-Aldosterone System on Artery Structure

Although the hemodynamic effects of hypertension are undoubtedly an important trigger of remodeling, studies suggest that circulating factors known to be elevated in hypertensive subjects play a major role in the process independent of blood pressure. The renin-angiotensin-aldosterone system (RAAS) has been well studied in this regard. Many studies have been conducted using angiotensin-converting enzyme inhibitors (ACEIs) (36, 82) or angiotensin receptor blockers (27, 60). These studies compared the effects of RAAS inhibition with blood pressure lowering by RAAS-independent means using β-blockers. The take home message from these studies is that blood pressure lowering alone is not sufficient to improve pial artery (27, 82) or MCA structure (116, 212) in SHRSP or SHR. β-Blockers do not improve artery structure, yet they reduce plasma renin activity and angiotensin-II (ANG II) levels (17). It is not clear why β-blockers and ACEIs do not have similar effects on artery structure because both reduce ANG II and lower blood pressure. A role for ANG II in cerebral artery remodeling is supported by studies using angiotensinogen knockout mice. The internal diameter of the anterior cerebral artery-MCA anastomoses is increased in the knockout mice compared with wild-type mice, but there was no difference in the number of anastomoses. It is possible that the lower blood pressure observed in the knockout mice affected artery structure (127).

Of particular note is a study documenting a reduction in wall thickness and wall-to-lumen ratio in aged SHR with ACEIs. In this study, rats began the captopril treatment at 12 mo of age and were studied at 15 mo. Thus the rats began treatment when they were already hypertensive and when vascular remodeling would be present. Therefore, the hypertension-induced remodeling in the pial arteries appears to be reversible (59). The same researchers recently demonstrated that low doses of ACEIs (ramapril) and angiotensin receptor blockers (telmisartan) in combination are effective at improving pial artery structure and function in young SHR. The same doses of these drugs given alone had essentially no effects on pial arteries (61). It is also worth noting that the combination therapy was not any more effective than a higher dose of either drug used alone (60). In both cases the therapies that improved artery structure also significantly reduced blood pressure. Although many of the studies described above assessed blood flow and found it to be improved (59–61), it remains to be seen whether these structural changes improve blood flow after an insult like cerebral ischemia. One thing lacking in these studies is a mechanism by which the artery structure changes and this is the next important step to take, as there may be more efficacious therapeutic candidates.

Our laboratory has taken the analysis of the effect of RAAS on cerebral arteries a step further by investigating the effects of aldosterone and activation of its receptor, the mineralocorticoid receptor, on cerebral artery remodeling. Treatment of SHRSP from 6–12 wk of age with spironolactone, a mineralocorticoid receptor antagonist, prevents the reduction in lumen diameter and increase in wall-to-lumen ratio in the MCA associated with elevated blood pressure (174). Spironolactone also increases the MCA lumen diameter in rats with established hypertension and remodeling (173). Importantly, in both studies the beneficial effects of mineralocorticoid receptor antagonism occurred without reducing blood pressure. Conversely, mineralocorticoid receptor activation with DOCA or 11-β-hydroxysteroid dehydrogenase inhibition in normotensive rats leads to MCA remodeling including increased wall-to-lumen ratio and reduced lumen diameter (54, 156). In both of these studies there was a mild to moderate increase in systolic blood pressure and a marked increase in the damage caused by cerebral ischemia induced by MCA occlusion. We have yet to elucidate whether the effects of ANG II and aldosterone are dependent on each other or additive. However, the lack of an effect of mineralocorticoid receptor antagonism on blood pressure suggests that the mechanisms responsible for the effects of aldosterone on the cerebral arteries differ from those mediated by ANG II.

Many intracellular signaling cascades activated by the RAAS could stimulate artery remodeling. ANG II and aldosterone have been linked to the production of reactive oxygen species (ROS), particularly superoxide, through NADPH-oxidase induction (171, 198). Superoxide has been implicated in the remodeling of peripheral resistance arteries (165) and coronary arteries (19) in hypertensive rats. In fact, treatment of SHRSP with the membrane permeable superoxide dismutase (SOD)-mimetic Tempol prevented the reduction in the MCA lumen diameter normally observed in SHRSP (167). For artery remodeling to occur, the extracellular matrix needs to be degraded and reorganized to allow for the movement of SMCs within the wall. The matrix metalloproteinase (MMP) family of enzymes appears to be responsible for this process (73), and MMP expression is modulated by RAAS activation. Mineralocorticoid receptor antagonism reduces MMP-13 mRNA expression in large cerebral arteries from SHRSP (173). Moreover, treatment of SHRSP with the nonspecific MMP inhibitor doxycycline increases the lumen diameter and reduces the wall-to-lumen ratio in MCAs from 12-wk-old SHRSP. These changes in structure occurred without lowering arterial pressure. Doxycycline treatment also reduced the amount of damage produced by MCA occlusion with reperfusion, and increased pial artery blood flow post-stroke as measured with scanning laser Doppler (168). In this study the doxycycline treatment was removed several days before the induction of cerebral ischemia. Therefore, the reduction in infarct size was not likely a response to acute MMP inhibition at the time of the stroke. We do not know whether Tempol or doxycycline affect the pial, penetrating, or parenchymal arterioles in hypertensive rats.

Non-RAAS-Dependent Mechanisms of Cerebral Artery Remodeling

There is a growing body of evidence suggesting that other mechanisms also contribute to hypertensive cerebral artery remodeling. Peroxisome proliferator-activated receptor-γ activation with rosiglitazone prevented inward remodeling of the posterior cerebral artery (PCA) in l-NAME hypertensive rats. In this study, mean arterial pressure was already increased by l-NAME before the rosiglitazone treatment began, and rosiglitazone had no effect on blood pressure (31). Similarly, treatment of New Zealand genetically hypertensive rats with pioglitazone reduced media thickness of the basilar artery; in this study blood pressure was reduced by pioglitazone (119). 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) also have the potential to prevent hypertensive cerebral artery remodeling. Simvastatin reduced the wall thickness and increased the lumen diameter of the basilar artery in genetically hypertensive rats (118) and in the 2K2C hypertensive rat (125). In both these studies simvastatin lowered the blood pressure. Thus it is not clear whether the prevention of hypertension induced remodeling is a direct effect of the statin therapy or a response to the lower blood pressure.

Chloride Channels and Cerebral Artery Remodeling

Hypertrophic remodeling involves an increase in the mass of the artery wall. This can be the result of SMC hypertrophy where the cell volume increases, or it can be the result of hyperplasia or SMC proliferation. Both situations require changes in cell volume. which is tightly controlled by membrane transport processes that regulate the gain or loss of ions, such as Na+, K+, and Cl or small organic osmolytes including amino acids, polyols, and methylamines (192). The following paragraphs discuss the importance of two Cl channels in cerebral artery remodeling. It should be recognized that several other ion channels have been implicated in the cerebral artery remodeling process, including receptor- and store-operated Ca2+ channels (22), transient receptor potential (TRP) channels (99), large-conductance Ca2+-activated K+ channels (BKCa), and voltage-gated K+ channels (211). We have chosen to focus on Cl channels because this is an area that is somewhat controversial.

The volume-regulated Cl channel (ICl.vol), appears to be a key regulator of artery remodeling. Activation of this channel has been implicated in the control of SMC volume, proliferation, and apoptosis (80). The exact identity of the ICl.vol channel is not clear, but CIC-3, a voltage-gated Cl channel, is considered a prime candidate in vascular SMCs (80, 216). Blockers of ICl.vol hyperpolarize rat cerebral artery SMCs, and this results in dilation (151). Therefore, activation of ICl.vol appears to cause SMC depolarization and artery constriction. In basilar arteries from 2K2C rats, SMC hypertrophy is observed, and this increased cell size results in an increased medial area. Cultured SMCs from these arteries show a blood pressure-dependent increase in ICl.vol activity when placed in a hypotonic solution, and this increased activity requires protein tyrosine kinase activation (180). Treatment of 2K2C rats with simvastatin reduces the activity of this channel, and simvastatin attenuates basilar artery remodeling (125). It is also possible that the contribution of these channels to hypertensive remodeling is through depolarization-induced opening of voltage-gated Ca2+ channels, leading to an increase in intracellular calcium and activation of Ca2+-dependent SMC proliferation (44, 169). This hypothesis remains untested. It is also unclear whether the changes in the activity of the Cl channels are a cause or an effect of hypertensive artery remodeling. However, the CIC-3 may be particularly important in hypertension because it is activated by many factors that are known to be elevated in, or associated with, hypertension including ANG II, endothelin-1, and ROS (55).

Other studies suggest that Ca2+-activated Cl channels are involved in the hypertensive remodeling process. As with the ICl.vol, the molecular identity of Ca2+-activated Cl channels has been difficult to define. Wang et al. (206) used the 2K2C rats to test the involvement of the TMEM16 family of transmembrane proteins in the regulation of the Ca2+-activated Cl current with a particular focus on TMEM16A. Interestingly, the activity of the channel and therefore the Ca2+-activated Cl current is reduced in SMCs from hypertensive arteries compared with arteries from control rats. ANG II reduced TMEM16A expression, and overexpressing TMEM16A reduced ANG II-stimulated SMC proliferation (206). The authors of this study proposed that the TMEM family proteins are potential therapeutic targets for vascular disease.

Hemodynamic Effects of Vascular Remodeling

The hemodynamic effects of vascular remodeling are severalfold. In hypertensive patients, the remodeling process functions to normalize, or partially reduce, blood flow in the face of increased blood pressure by increasing vascular resistance (104, 111). Whereas many studies suggest resting blood flow is relatively normal in hypertensive individuals, there is some evidence that in older hypertensive patients, blood flow is reduced in specific brain regions including the occipitotemporal and prefrontal cortex and the hippocampus (15). Hypertension also impairs functional hyperemia (104), which is the increase in blood flow to regions of increased neuronal activity. Functional hyperemia requires the release of vasoactive agents from neurons, astrocytes, and the vessels themselves to cause local dilation in the parenchymal arterioles and the upstream pial arteries (95). Hypertensive patients with poorly controlled blood pressure have a decline in total cerebral blood flow as they age. This occurs independent of atherosclerosis (142) and may be a consequence of impaired cerebral artery structure and function. Hypertension also increases the lower limit of autoregulation, and this can severely impact the outcome of cerebral ischemia and the regulation of cerebral blood flow during periods of hypotension. This will be discussed in more detail below.

Cerebral Artery Function in Hypertension

As mentioned above, cerebral blood flow is controlled by more than just the passive structure of the artery. Studies of how cerebral arteries contract and dilate are vital, and this area of research is moving rapidly, although very little work has been conducted comparing hypertensive and normotensive subjects.

Cerebral Artery Autoregulation

One striking characteristic of the cerebral circulation is its ability to maintain the parenchymal perfusion at relatively constant levels over a wide range of arterial pressures; this occurs through the mechanism of autoregulation. In most adult humans autoregulation operates between mean arterial pressures of 60 and 150 mmHg (166). When the cerebral perfusion pressure rises above or falls below the autoregulatory range, the control of flow is lost and flow becomes dependent on mean arterial pressure (158). Pressures above the autoregulatory range cause increases in blood flow followed by vasogenic edema. Conversely, pressures below the autoregulatory range result in low perfusion of the brain and subsequent ischemic injury (30). Several mechanisms have been proposed to contribute to the control of autoregulation in the cerebral circulation. These include neuronal NO production (56, 106, 166, 195) and metabolic by-products (166). The sympathetic and parasympathetic nervous systems were not thought to be involved in cerebral blood flow autoregulation (21); however, recent studies in humans have suggested a role for both dynamic sympathetic vasoconstriction (84) and cholinergic vasodilation (85) in the control of cerebral autoregulation. Blood flow itself also plays a role in autoregulation, and this concept was recently reviewed by Koller and Toth (115). This review describes the evidence that flow can induce contraction or dilation in the cerebral vasculature dependent on the artery studied. For example, the basilar artery dilates in response to increased flow, whereas the MCA constricts.

Myogenic Reactivity

The myogenic activity of the cerebral arteries also plays an important role in cerebral blood flow autoregulation. Myogenic reactivity is the ability of the artery to change its tone to respond to fluctuations in intralumenal pressure while keeping blood flow constant as first described by Bayliss in 1902 (14). This is particularly important at higher pressures when the arteries constrict to maintain blood flow at a constant level (Fig. 2) (158). Basal vascular tone contributes to cerebrovascular resistance, and much of this tone is thought to be myogenic in nature (68). Cerebral arteries from normotensive rats maintain myogenic reactivity over a range of intralumenal pressures from about 60 to 140 mmHg. The myogenic response is an intrinsic property of SMC to stretch that is in part controlled by 20-HETE production (75). The extent and duration of the response is modulated by the endothelium and removing the endothelium increases myogenic tone (35, 74). The endothelium modulates myogenic reactivity through many mechanisms, several of which are impaired in other vascular beds in subjects with hypertension (137). NO (69), prostacyclin (128), and endothelium-derived hyperpolarizing factor (EDHF) (78) are all released from the endothelium and have the ability to reduce myogenic constriction. Conversely, 20-HETE production is increased in cerebral vessels from hypertensive rats, and this could increase the myogenic tone (58).

Fig. 2.

Fig. 2.

Cerebral blood flow in relation to artery lumen diameter. Dotted lines represent the lower and upper limits of cerebral blood flow autoregulation. Red circles represent the cerebral arteries, and blue line represents the cerebral blood flow. Modified from Mangat (129); used with permission.

Myogenic responses are frequently studied ex vivo using pressure myograph systems that allow the responses of the artery to pressure and stretch to be studied without the confounding effects of circulating factors or metabolites. Osol et al. (158) have described in vitro myogenic behavior of the PCA as occurring in three stages. Phase 1 is the development of tone that occurs at intralumenal pressures of 40–60 mmHg and involves SMC depolarization, increases in intracellular calcium, and reductions in vessel tension and tangential stress. Phase 2 is described as myogenic reactivity that occurs between 60 and 140 mmHg intralumenal pressure. In this phase, the tone developed in phase 1 is maintained despite the increase in wall tension and intralumenal pressure. Finally, phase 3 is force-mediated dilation. This occurs when the intraluminal pressure increases to a level where tangential wall stress exceeds the ability of SMCs to contract and generate active wall stress to oppose the pressure-induced stress, resulting in forced dilation (158).

Despite the potential importance of studying autoregulation and myogenic reactivity in models of hypertension, the available studies are limited and conflicting. Pressure myograph studies have shown that PCAs from normotensive WKY rats exhibit myogenic reactivity over a range of intralumenal pressures from ∼40 to 150 mmHg, after which force-mediated dilation occurs. In SHRs, myogenic reactivity occurs over a higher range of pressures from ∼65 to 190 mmHg (159). Another study showed that myogenic tone generated over a wide range of intralumenal pressures is increased in PCAs from SHR compared with WKY rats. However, the pressure at which force mediated dilation occurs was the same in both strains (103). MCAs from male SHRSP-fed regular chow show similar myogenic responses to WKY rats. Interestingly, the SHRSP females, which have lower pressure than males, exhibited relatively more myogenic constriction than female WKY rats (96). When fed a high-salt diet, MCA from SHRSP lose their ability to constrict in response to increasing intralumenal pressure (101). Consequently, the downstream arterioles and capillaries will be exposed to higher pressures and increased flow, increasing the probability of a cerebral hemorrhage and edema. In fact, SHRSP fed a high-salt diet from weaning have an almost complete loss of autoregulation at 13 wk of age, the age at which they start to develop hemorrhagic strokes. The loss of autoregulation is accompanied by a pressure-dependent increase in cerebral blood flow (186), suggesting the high intralumenal pressure is transferred to downstream arterioles. The mechanism responsible for the loss of regulation in the salt-loaded SHRSP has not been identified, although the potential exists that this is a physical response to the increased blood pressure. The administration of a high-salt diet to SHRSP increases their blood pressure by 10 to 20 mmHg compared with control chow-fed SHRSP (79, 100).

Most studies of autoregulation have focused on the upper end of the autoregulatory curve. However, we may be missing important physiological effects by not considering the low-pressure end of the curve, which is referred to as the lower limit of cerebral blood flow regulation. This is the pressure below which blood flow becomes dependent on blood pressure. In this situation the autoregulatory mechanisms cannot produce further dilation and the arteries begin to collapse because the intralumenal pressure is low. This causes blood flow to fall (Fig. 2). The lower limit of autoregulation is increased in animal models and patients with hypertension (6). In SHR and in rats with renal hypertension normalizing blood pressure with ACEIs reduces the lower limit of cerebral blood flow regulation (7, 59, 204). Improving the lower limit of blood flow regulation could be important in situations like cerebral ischemia. During occlusion of a major blood vessel, the intralumenal pressure in arteries downstream from the occlusion drops and normally induces vasodilation. However, if the pressure drops below the lower limit of blood flow regulation, the diameter of the artery will be exclusively dependent on its passive diameter. Because arteries from hypertensive subjects have smaller passive diameters, this can further compromise perfusion and increase hypoxic areas.

Endothelial Mechanisms that Regulate Cerebral Vessel Tone: NO-Dependent Mechanisms

The best described mechanism for endothelial regulation of vascular tone is NO (Fig. 3). The enzyme endothelial NO synthase (eNOS) is the most important source of NO in cerebral arteries, and eNOS expression is reduced in cerebral microvessels from SHR compared with WKY rats (212). This impairs endothelium-dependent dilation, which could be detrimental to the outcome of ischemia because maximal dilation of the collateral vessels is required to circumvent an occlusion and minimize hypoxia and neuronal death (40). In support of this hypothesis, eNOS knockout mice have impaired cerebral perfusion following MCA occlusion, and this increases the ischemic damage (93). Some therapeutic agents have been shown to improve the outcome of MCA occlusion through pleiotropic mechanisms that increase eNOS activity. Such is the case for cilostazol, a phosphodiesterase-3 inhibitor and antiplatelet medication. In SHR, cilostazol increased phosphorylated eNOS (active eNOS) levels in the brain, and this was associated with increased cerebral blood flow after ischemia and reduced infarct size (160). Similarly, in SHRSP fed a high-fat diet, cilostazol prevented the reduction in cerebral blood flow observed in untreated SHRSP or SHRSP treated with aspirin or clopidogrel. This suggests that the effects of cilostazol are not related to its antiplatelet activity (155) and that cilostazol may improve endothelial function in SHRSP. This is clinically relevant, as recently evidenced by the Cilostazol Stroke Prevention Study showing that cilostazol is effective in preventing secondary ischemic strokes in patients independent from its effects on platelet aggregation (181).

Fig. 3.

Fig. 3.

Recent advances in cerebral artery function. Five major recent findings are summarized: 1) transient receptor potential vanilloid 4 (TRPV4) channels in endothelial cells (ECs) and are coupled to muscarinic receptor activation and generate a calcium sparklet, which opens intermediate-conductance and small-conductance Ca2+-activated K+ channels (IKCa and SKCa, respectively), leading to K+ efflux and hyperpolarization. The hyperpolarization is then transmitted to smooth muscle cells (SMCs) through myoendothelial junction. It is still unknown whether this system is present in ECs of cerebral arteries and how hypertension might affect it (question mark in the figure); 2) pleiotropic effects of drugs: cilostazol, an antiplatelet drug, improves endothelial function in hypertensive rats by increasing phosphorylation of the endothelial NOS (eNOS), the active form of this enzyme. Resveratrol, an antioxidant, also increases eNOS function. The net result is an increase in NO bioavailability, which is known to be reduced in hypertensive EC (blue); 3) epoxyeicosatrienoic acids (EETs) are arachidonic acid (AA) metabolites that cause cerebral artery dilation. EETs activate TRPV4 channels that allow for a small calcium influx that opens ryanodine receptors (RyRs) in the sarcoplasmic reticulum. RyR causes a local and transient increase in intracellular calcium, a calcium spark, which opens large-conductance Ca-activated K+ channels (BKCa), leading to efflux of K+ and hyperpolarization. The soluble epoxide hydrolase (sEH) inactivates EETs to dihydroxyeicosatrienoic acids (DHETs) and may be increased in hypertension (red); 4) many vasoactive peptides, including angiotensin II and endothelin-1, increase the activity of the enzyme NADPH oxidase, causing accumulation of superoxide anion. Superoxide can be dismutated into hydrogen peroxide by the superoxide dismutase enzyme (SOD), or it can react with NO, blunting NO availability. Paradoxically, SOD expression is increased in hypertension, possibly leading to increased hydrogen peroxide production. Hydrogen peroxide activates Ca2+ sparks and BKCa in SMCs, and it is possible that it accomplished that through activation of TRPV4 channels; 5) transient receptor potential 3 (TRPC3) channels, found exclusively in SMCs, are overexpressed in hypertensive carotid arteries and are involved in the vasoconstriction caused by UTP. Opening of TRPC3 channels causes a localized depolarization that opens L-type Ca2+ channels, leading to SMC depolarization and vasoconstriction. Cyp, cytochrome P-450; RAAS, renin-angiotensin-aldosterone system.

NO-dependent dilation is also impaired by oxidative stress that is elevated in hypertensive arteries (197). Under physiological circumstances, superoxide is dismutated into hydrogen peroxide in a reaction catalyzed by SOD. However, excessive superoxide production might saturate the SOD defenses, leaving superoxide to react with NO and reduce the NO availability in the cerebral arteries, leading to impaired endothelial function (164). Interestingly, in normotensive rats, superoxide production in cerebral arteries is twofold higher than in peripheral arteries (138). This is in agreement with a paradoxical effect of ROS in pial arteries, where hydrogen peroxide acts as a vasodilator by activating BKCa (187). However, the effects of hydrogen peroxide on the cerebral vasculature vary with the artery studied. Hydrogen peroxide causes MCA constriction by opening L-type Ca2+ channels (24). Surprisingly, superoxide is not detected in the basilar artery of SHR under physiological conditions. This could be a consequence of SOD overexpression, because SOD inhibition raised superoxide levels above the detection limit (163). SOD may be overexpressed in response to the excessive production of superoxide and may provide an alternative vasodilator mechanism after a chronic depletion in NO (Fig. 3).

Endothelial Mechanisms that Regulate Cerebral Vessel Tone: NO-Independent Dilation

Endothelium-dependent dilation in cerebral arteries has a component which is NO and prostacyclin independent. This mechanism of dilation is referred to as EDHF (Fig. 3) (20). The exact identity of EDHF is under debate, but calcium-activated K+ channels, particularly the small- and intermediate-conductance Ca2+-activated K+ channels (SKCa and IKCa, respectively), appear to be involved (191). Deletion of IKCa in mice leads to systemic hypertension and impairment of acetylcholine dilation in carotid arteries (182). In the MCA, a large component of EDHF vasodilation depends on IKCa (131), but it is still unclear whether protein levels of IKCa are decreased in cerebral arteries of hypertensive subjects. Importantly, IKCa expression is increased in mesenteric resistance arteries from SHRSP, but EDHF dilation is impaired (76), suggesting that loss of IKCa channel expression is not sufficient to explain EDHF-impairment.

A role for TRP channels in the control of cerebral artery endothelial function has recently emerged (Fig. 3). This is one of the most exciting and rapidly evolving areas of cerebral vascular research. The TRP superfamily of cation channels comprises 28 channels divided into 6 families. These channels are non-selective for cations, and different channels subtypes have differential selectivity for monovalent or divalent cations, although they will conduct both [for a review of TRP channel biology, see the following articles (63, 203)]. TRPC3 is found in cerebral arteries and mediates vasoconstriction (172). Its expression is increased in carotid arteries from SHR, and this is linked to augmented contractility (154). To date, no one has assessed whether TRPC3 expression is increased in cerebral arteries.

The TRP vanilloid 4 (TRPV4) channel is activated by epoxyeicosatrienoic acids (EETs) and contributes to cerebral artery endothelium-dependent dilation (62, 64). The mechanisms of TRPV4 hyperpolarization differ between vascular SMCs and endothelial cells. In vascular SMCs, TRPV4 channels form a novel signaling complex with ryanodine receptors (RyRs) and BKCa (64). Upon opening, TRPV4 channels allow for a small Ca2+ influx that opens RyRs on the sarcoplasmic reticulum, generating a transient and localized increase in Ca2+, known as calcium sparks. These calcium sparks increase BKCa, opening leading to K+ efflux and hyperpolarization (64). In endothelial cells of mesenteric resistance arteries, activation of muscarinic receptors increases the opening of a small number of TRPV4 channels, generating a calcium sparklet, which are transient increases in intracellular calcium at the mouth of a single channel (25). This calcium sparklet activates IKCa and SKCa in the endothelial cells, leading to hyperpolarization that is transmitted to the SMCs via gap junctions (189). It is important to note that calcium sparklets also occur in SMCs but are not mediated by TRPV4. TRPV4 knockout does not cause hypertension, but it exacerbates l-NAME-induced hypertension and is linked to impairment in endothelium-dependent dilation in peripheral arteries (65). Interestingly, ROS can activate Ca2+ sparks in cerebral arteries, coupling this signal to RyRs and BKCa (210), potentially through TRPV4 activation. Despite the importance of TRPV4 in regulating endothelial function in cerebral arteries, it is unknown whether their expression and function is altered in the cerebral vasculature of hypertensive subjects.

As described above, functional hyperemia causes local dilation in the parenchymal arterioles and the upstream pial arteries (95). In parenchymal arterioles, vasodilation is a consequence of paracrine release of vasodilators such as EETs from perivascular astrocytes (86) and neurons (97). Functional hyperemia is impaired in rats with ANG-II hypertension (77) and in untreated hypertensive humans (104). Although the mechanisms regulating functional hyperemia are not fully understood, it is dependent on NO (51, 122), cyclooxygenase-2 metabolites (153), and, more importantly, EETs (176). EETs are synthesized from arachidonic acid by cytochrome P-450 enzymes and metabolized into inactive compounds by soluble epoxide hydrolase (Fig. 3) (214). EETs act directly on SMCs to cause vasodilation, through an undefined mechanism. One possibility is direct activation of TRPV4 channels by EETs (64, 205). TRPV4 activation leads to Ca2+ spark formation that leads to BKCa activation and dilation as described above (64). Inhibition or deletion of soluble epoxide hydrolase reduces blood pressure in many models of hypertension, including ANG-II hypertension (98), 2K1C (190), and DOCA-salt (130). Soluble epoxide hydrolase inhibition does not lower blood pressure in SHRSP, but it does reduce ischemic damage after MCA occlusion (53). This appears to occur through a combination of vascular and neuroprotective effects (53, 184). Although cerebral perfusion was not evaluated in those studies, it is possible that soluble epoxide hydrolase inhibition caused an increase in EET availability to the cerebral vasculature after ischemia, leading to augmentation in collateral blood flow to the ischemic penumbra and reduction in hypoxic neuronal death. In agreement with this possibility is the observation that cerebral arteries from SHR have decreased production of 11,12-EET (58). 20-HETE, another arachidonic acid metabolite, causes cerebral artery contraction. The increased NO production observed in functional hyperemia reduces 20-HETE synthesis or signaling, and this allows the EET-dependent dilation to be apparent (124).

Hypertension and BBB Function

The structure and function of the BBB has been eloquently reviewed (2). In our introduction we described the basic architecture of the cerebral microvessels where most studies of BBB function have been conducted. It is important to note that the BBB is not limited to the small vessels. The endothelial cells in the pial, penetrating, and parenchymal arteries also exhibit BBB properties (1, 175, 217), although BBB function is not frequently studied in these arteries. The BBB is a selectively permeable physical and biochemical barrier that maintains central nervous system homeostasis. The permeability properties of the BBB are derived from the composition of the neurovascular unit. The capillaries are lined by specialized endothelial cells that express transmembrane tight junction proteins including the claudins and occludins. Although most studies of the BBB focus on the endothelial cells, it should be noted that pericytes (123, 178, 202) and astrocytes (66) play key roles in barrier maintenance. We know little about how hypertension affects the contribution of astrocytes and pericytes to BBB function. It is possible that hypertension increases the number of pericytes, this was found to be the case in kidney from SHR (8).

Hypertension enhances BBB permeability and impairs its ability to regulate central nervous system homeostasis (90, 135, 161). Studies using SHRSP reveal that with chronic hypertension, there is evidence of intrinsic leakiness of the barrier that, in the absence of ischemia and hemorrhage, results in edema (196). The increased BBB permeability associated with hypertension is attenuated by ACE inhibition (150). In rats with renal hypertension, enalapril significantly reduced cortical BBB permeability and macrophage infiltration into arterioles. In this study, enalapril treatment begun after the hypertension was developed did not completely ameliorate the increase in blood pressure (150). Vascular remodeling that occurs in response to hypertension (described above) could also contribute to BBB breakdown (148). It should be noted the blood pressure was extremely high (220 mmHg systolic pressure) in the rats exhibiting the most marked BBB disruption, and therefore the potential exists that the damage to the BBB is purely a physical insult. However, the idea that artery remodeling contributes to BBB breakdown has some merit. During the remodeling process, arterial structure becomes more dynamic than when it is under normal physiological conditions, and in some cases the lumen becomes smaller, which requires rearrangement of the endothelial cells and therefore tight junction disruption. Paradoxically, the BBB in chronically hypertensive animals is more resistant to acute increases in blood pressure, possibly due to the protective effect of adaptive changes in the structure of the BBB (141). Although no studies have directly assessed why hypertension protects the BBB from acute changes in pressure, recent studies suggest that sheer stress may be involved. Preconditioning aortic endothelial cells to fluctuations in shear stress leads to a transient increase in membrane permeability, but it also promotes the expression of anti-inflammatory and antioxidant genes (81, 94, 215). This adaptive response could contribute to the resistance of chronically hypertensive animals to acute hypertension-mediated disruption of BBB.

There are few studies describing the mechanisms by which chronic hypertension increases BBB permeability but ROS and inflammation are potential mediators of hypertension-induced BBB breakdown (132, 193). Increased ROS production has several consequences in the vasculature including endothelial cell dysfunction, which can lead to increased BBB permeability (200, 209). An in vitro study in which human umbilical vein endothelial cells were treated with hydrogen peroxide indicated that oxidative stress causes reorganization of tight junctions (112). A recent study of the effects of peripheral inflammatory pain induced by λ-carrageenan injection into the paw on BBB permeability demonstrated that the ROS scavenger Tempol reduced the disruption of tight junctions and attenuated the damage caused by the inflammation (126). In another study, the ROS generating enzyme NADPH oxidase was shown to partially mediate BBB disruption after experimental stroke. In this study, NADPH oxidase knockout mice had reduced BBB permeability after MCA occlusion compared with wild-type mice (108).

Clinical and experimental studies have shown that hypertension increases circulating levels of inflammatory cytokines such as tumor necrosis factor-α, interleukin 6, monocyte chemoattractant protein 1, and intercellular adhesion molecule-1 in the vasculature (71, 179, 218). Several studies show that inflammation can induce BBB opening. A study examining the effects of microglia on the BBB reported that endothelial cells cocultured with microglia are more susceptible to changes in the environment like glucose deprivation and ischemia (213). The same study showed that in vivo, mice treated with the anti-inflammatory agent minocycline had reduced BBB permeability and reduced infarct volume after stroke (213). Minocycline also inhibits MMP activity and which could reduce BBB breakdown. Similarly, systemic inflammation worsens BBB injury leading to edema in an experimental model of stroke (48).

Conclusions and Outstanding Questions

Hypertension has detrimental effects on the cerebral vasculature, which include changes in the structure and function of the arteries. There are, however, several gaps in our knowledge. Most studies conducted thus far have used relatively young, predominantly male rats or mice, yet cerebrovascular dysfunction primarily occurs in diseases of the elderly. We have learned much about how to prevent cerebrovascular disease, but we know much less about how to reverse it.

There is also a need to consider hypertension effects on the cerebrovascular response to ischemia. Myogenic tone and reactivity in cerebral arteries fall with increasing durations of ischemia (33), and endothelium-dependent dilation is impaired soon after the onset of ischemia (134, 177). Several studies indicate that during transient MCA occlusion the nonischemic MCA experiences vascular dysfunction (32–34, 105). Other studies indicate that dilation of the basilar artery is impaired post-stroke (39). Impaired artery function post-stroke also extends to the mesenteric arterial bed in the periphery (133). We do not know how the structural changes that occur with hypertension affect the vascular response to ischemia. We also do yet know the effects of sex and age on the vascular responses to an ischemic insult. Studies using a global forebrain ischemia model suggest that estrogen prevents the impaired dilation normally observed in pial arteries after induction of ischemia (170, 207). It is not clear whether this protection remains in hypertensive rats.

Not only do the cerebral vessels play a critical role in the outcome of ischemia, it is also becoming clear that vascular dementia and cognitive decline are important clinical problems that have a vascular basis. SHRSP have proven to be useful models to study vascular dementia. These rats develop many of the histopathological lesions also observed in humans with vascular dementia, such as multiple lacunar infarcts, cerebral atrophy and neuronal loss from cognitive regions of the cortex (114). It is possible that these lesions in SHRSP are due to declines in cerebral perfusion, since this correlation was recently observed in humans (136). As our population ages the incidence of stroke and vascular dementia will most probably increase highlighting the need to define ways to prevent or reverse the effects of hypertension on the vasculature. These studies will requires that penetrating and parenchymal arterioles be given more consideration. It is also important to correlate findings in the vasculature with behavioral and neurological function testing.

GRANTS

This study was funded by the American Heart Association, P. W. Pires and C. M. Dams Ramos are both recipients of AHA predoctoral fellowships, and A. M. Dorrance has received an American Heart Association Established Investigator Award 0840122N.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS

P.W.P. performed experiments; P.W.P. analyzed data; P.W.P. interpreted results of experiments; P.W.P. and A.M.D. prepared figures; P.W.P., C.M.D.R., N.M., and A.M.D. drafted manuscript; P.W.P., C.M.D.R., N.M., and A.M.D. approved final version of manuscript; P.W.P., C.M.D.R., N.M., and A.M.D. edited and revised manuscript; A.M.D. conception and design of research.

ACKNOWLEDGMENTS

We thank Dr. Sue Barman, Dr. William Jackon and Dr. Stephanie Watts for their editorial comments. The authors also thank Daniel Bollman for producing the image of the cerebral arteries in Fig. 1A.

REFERENCES

  • 1. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 20: 131–147, 2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13–25, 2010. [DOI] [PubMed] [Google Scholar]
  • 3. Arribas SM, Costa R, Salomone S, Morel N, Godfraind T, McGrath JC. Functional reduction and associated cellular rearrangement in SHRSP rat basilar arteries are affected by salt load and calcium antagonist treatment. J Cereb Blood Flow Metab 19: 517–527, 1999. [DOI] [PubMed] [Google Scholar]
  • 4. Arribas SM, Gonzalez C, Graham D, Dominiczak AF, McGrath JC. Cellular changes induced by chronic nitric oxide inhibition in intact rat basilar arteries revealed by confocal microscopy. J Hypertens 15: 1685–1693, 1997. [DOI] [PubMed] [Google Scholar]
  • 5. Arribas SM, Gordon JF, Daly CJ, Dominiczak AF, McGrath JC. Confocal microscopic characterization of a lesion in a cerebral vessel of the stroke-prone spontaneously hypertensive rat. Stroke 27: 1118–1122, 1996. [DOI] [PubMed] [Google Scholar]
  • 6. Barry DI. Cerebral blood flow in hypertension. J Cardiovasc Pharmacol 7, Suppl 2: S94–S98, 1985. [DOI] [PubMed] [Google Scholar]
  • 7. Barry DI, Paulson OB, Jarden JO, Juhler M, Graham DI, Strandgaard S. Effects of captopril on cerebral blood flow in normotensive and hypertensive rats. Am J Med 76: 79–85, 1984. [DOI] [PubMed] [Google Scholar]
  • 8. Baumann M, van Essen H, Hermans JJ, Smits JF, Struijker-Boudier HA. Functional and structural postglomerular alterations in the kidney of prehypertensive spontaneously hypertensive rats. Clin Exp Hypertens 26: 663–672, 2004. [DOI] [PubMed] [Google Scholar]
  • 9. Baumbach GL, Chillon JM. Effects of angiotensin-converting enzyme inhibitors on cerebral vascular structure in chronic hypertension. J Hypertens Suppl 18: S7–S11, 2000. [PubMed] [Google Scholar]
  • 10. Baumbach GL, Dobrin PB, Hart MN, Heistad DD. Mechanics of cerebral arterioles in hypertensive rats. Circ Res 62: 56–64, 1988. [DOI] [PubMed] [Google Scholar]
  • 11. Baumbach GL, Hajdu MA. Mechanics and composition of cerebral arterioles in renal and spontaneously hypertensive rats. Hypertension 21: 816–826, 1993. [DOI] [PubMed] [Google Scholar]
  • 12. Baumbach GL, Heistad DD. Cerebral circulation in chronic arterial hypertension. Hypertension 12: 89–95, 1988. [DOI] [PubMed] [Google Scholar]
  • 13. Baumbach GL, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 13: 968–972, 1989. [DOI] [PubMed] [Google Scholar]
  • 14. Bayliss WM. On the local reactions of the arterial wall to changes of internal pressure. J Physiol 28: 220–231, 1902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Beason-Held LL, Moghekar A, Zonderman AB, Kraut MA, Resnick SM. Longitudinal changes in cerebral blood flow in the older hypertensive brain. Stroke 38: 1766–1773, 2007. [DOI] [PubMed] [Google Scholar]
  • 16. Blanco VM, Stern JE, Filosa JA. Tone-dependent vascular responses to astrocyte-derived signals. Am J Physiol Heart Circ Physiol 294: H2855–H2863, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 12: 451–459, 1999. [DOI] [PubMed] [Google Scholar]
  • 18. Bohlen HG. The microcirculation in hypertension. J Hypertens Suppl 7: S117–S124, 1989. [PubMed] [Google Scholar]
  • 19. Bonacasa B, Sanchez ML, Rodriguez F, Lopez B, Quesada T, Fenoy FJ, Hernandez I. 2-Methoxyestradiol attenuates hypertension and coronary vascular remodeling in spontaneously hypertensive rats. Maturitas 61: 310–316, 2008. [DOI] [PubMed] [Google Scholar]
  • 20. Bryan RM, Jr, You J, Golding EM, Marrelli SP. Endothelium-derived hyperpolarizing factor: a cousin to nitric oxide and prostacyclin. Anesthesiology 102: 1261–1277, 2005. [DOI] [PubMed] [Google Scholar]
  • 21. Busija DW, Heistad DD. Factors involved in the physiological regulation of the cerebral circulation. Rev Physiol Biochem Parmacol 101: 161–211, 1984. [DOI] [PubMed] [Google Scholar]
  • 22. Cai BX, Li XY, Chen JH, Tang YB, Wang GL, Zhou JG, Qui QY, Guan YY. Ginsenoside-Rd, a new voltage-independent Ca2+ entry blocker, reverses basilar hypertrophic remodeling in stroke-prone renovascular hypertensive rats. Eur J Pharmacol 606: 142–149, 2009. [DOI] [PubMed] [Google Scholar]
  • 23. Chan SL, Cipolla MJ. Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-gamma. FASEB J 25: 3229–3239, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Chaplin NL, Amberg GC. Hydrogen peroxide mediates oxidant-dependent stimulation of arterial smooth muscle L-type calcium channels. Am J Physiol Cell Physiol 302: C1382–C1393, 2012. [DOI] [PubMed] [Google Scholar]
  • 25. Cheng H, Lederer WJ. Calcium sparks. Physiol Rev 88: 1491–1545, 2008. [DOI] [PubMed] [Google Scholar]
  • 26. Chillon JM, Baumbach GL. Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arteriolar dilatation in hypertensive rats. Hypertension 37: 1388–1393, 2001. [DOI] [PubMed] [Google Scholar]
  • 27. Chillon JM, Baumbach GL. Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arterioles in rats. Hypertension 33: 856–861, 1999. [DOI] [PubMed] [Google Scholar]
  • 28. Chillon JM, Baumbach GL. Effects of indapamide, a thiazide-like diuretic, on structure of cerebral arterioles in hypertensive rats. Hypertension 43: 1092–1097, 2004. [DOI] [PubMed] [Google Scholar]
  • 29. Chillon JM, Heistad DD, Baumbach GL. Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension 27: 794–798, 1996. [DOI] [PubMed] [Google Scholar]
  • 30. Cipolla MJ. The Cerebral Circulation (Colloquium Series in Integrated Systems Physiology: from Molecule to Function). San Rafael, CA: Morgan & Claypool Life Sciences, 2009. [PubMed] [Google Scholar]
  • 31. Cipolla MJ, Bishop N, Vinke RS, Godfrey JA. PPARγ activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats. Stroke 41: 1266–1270, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Cipolla MJ, Curry AB. Middle cerebral artery function after stroke: the threshold duration of reperfusion for myogenic activity. Stroke 33: 2094–2099, 2002. [DOI] [PubMed] [Google Scholar]
  • 33. Cipolla MJ, Lessov N, Hammer ES, Curry AB. Threshold duration of ischemia for myogenic tone in middle cerebral arteries: effect on vascular smooth muscle actin. Stroke 32: 1658–1664, 2001. [DOI] [PubMed] [Google Scholar]
  • 34. Cipolla MJ, McCall AL, Lessov N, Porter JM. Reperfusion decreases myogenic reactivity and alters middle cerebral artery function after focal cerebral ischemia in rats. Stroke 28: 176–180, 1997. [DOI] [PubMed] [Google Scholar]
  • 35. Cipolla MJ, Porter JM, Osol G. High glucose concentrations dilate cerebral arteries and diminish myogenic tone through an endothelial mechanism. Stroke 28: 405–410, 1997. [DOI] [PubMed] [Google Scholar]
  • 36. Clozel JP, Kuhn H, Hefti F. Effects of cilazapril on the cerebral circulation in spontaneously hypertensive rats. Hypertension 14: 645–651, 1989. [DOI] [PubMed] [Google Scholar]
  • 37. Cohen Z, Bonvento G, Lacombe P, Hamel E. Serotonin in the regulation of brain microcirculation. Prog Neurobiol 50: 335–362, 1996. [DOI] [PubMed] [Google Scholar]
  • 38. Cohen Z, Molinatti G, Hamel E. Astroglial and vascular interactions of noradrenaline terminals in the rat cerebral cortex. J Cereb Blood Flow Metab 17: 894–904, 1997. [DOI] [PubMed] [Google Scholar]
  • 39. Coucha M, Li W, Ergul A. The effect of endothelin receptor A antagonism on basilar artery endothelium-dependent relaxation after ischemic stroke. Life Sci 91: 676–680, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Coyle P. Dorsal cerebral collaterals of stroke-prone spontaneously hypertensive rats (SHRSP) and Wistar Kyoto rats (WKY). Anat Rec 218: 40–44, 1987. [DOI] [PubMed] [Google Scholar]
  • 41. Coyle P, Heistad DD. Blood flow through cerebral collateral vessels in hypertensive and normotensive rats. Hypertension 8: II67–II71, 1986. [DOI] [PubMed] [Google Scholar]
  • 42. Coyle P, Heistad DD. Blood flow through cerebral collateral vessels one month after middle cerebral artery occlusion. Stroke 18: 407–411, 1987. [DOI] [PubMed] [Google Scholar]
  • 43. Coyle P, Jokelainen PT. Differential outcome to middle cerebral artery occlusion in spontaneously hypertensive stroke-prone rats (SHRSP) and Wistar Kyoto (WKY) rats. Stroke 14: 605–611, 1983. [DOI] [PubMed] [Google Scholar]
  • 44. Cribbs LL. T-type Ca2+ channels in vascular smooth muscle: multiple functions. Cell Calcium 40: 221–230, 2006. [DOI] [PubMed] [Google Scholar]
  • 45. Davidson AO, Schork N, Jaques BC, Kelman AW, Sutcliffe RG, Reid JL, Dominiczak AF. Blood pressure in genetically hypertensive rats. Influence of the Y chromosome. Hypertension 26: 452–459, 1995. [DOI] [PubMed] [Google Scholar]
  • 46. De Ciuceis C, Porteri E, Rizzoni D, Rizzardi N, Paiardi S, Boari GE, Miclini M, Zani F, Muiesan ML, Donato F, Salvetti M, Castellano M, Tiberio GA, Giulini SM, Agabiti Rosei E. Structural alterations of subcutaneous small-resistance arteries may predict major cardiovascular events in patients with hypertension. Am J Hypertens 20: 846–852, 2007. [DOI] [PubMed] [Google Scholar]
  • 47. de la Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol 2012: 367516, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Dénes A, Ferenczi S, Kovács KJ. Systemic inflammatory challenges compromise survival after experimental stroke via augmenting brain inflammation, blood-brain barrier damage and brain oedema independently of infarct size. J Neuroinflammation 8: 164, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Deutsch C, Portik-Dobos V, Smith AD, Ergul A, Dorrance AM. Diet-induced obesity causes cerebral vessel remodeling and increases the damage caused by ischemic stroke. Microvasc Res 78: 100–106, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Dirnagl U. Pathobiology of injury after stroke: the neurovascular unit and beyond. Ann NY Acad Sci 1268: 21–25, 2012. [DOI] [PubMed] [Google Scholar]
  • 51. Dirnagl U, Niwa K, Lindauer U, Villringer A. Coupling of cerebral blood flow to neuronal activation: role of adenosine and nitric oxide. Am J Physiol Heart Circ Physiol 267: H296–H301, 1994. [DOI] [PubMed] [Google Scholar]
  • 52. Dorrance AM, Pollock DM, Romanko OP, Stepp DW. A high-potassium diet reduces infarct size and improves vascular structure in hypertensive rats. Am J Physiol Regul Integr Comp Physiol 292: R415–R422, 2007. [DOI] [PubMed] [Google Scholar]
  • 53. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46: 842–848, 2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Dorrance AM, Rupp NC, Nogueira EF. Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 47: 590–595, 2006. [DOI] [PubMed] [Google Scholar]
  • 55. Duan DD. The ClC-3 chloride channels in cardiovascular disease. Acta Pharmacol Sin 32: 675–684, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Duchemin S, Boily M, Sadekova N, Girouard H. The complex contribution of NOS interneurons in the physiology of cerebrovascular regulation. Front Neural Circuits 6: 51, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Duckworth JW, Wellman GC, Walters CL, Bevan JA. Aminergic histofluorescence and contractile responses to transmural electrical field stimulation and norepinephrine of human middle cerebral arteries obtained promptly after death. Circ Res 65: 316–324, 1989. [DOI] [PubMed] [Google Scholar]
  • 58. Dunn KM, Renic M, Flasch AK, Harder DR, Falck J, Roman RJ. Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 295: H2455–H2465, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Dupuis F, Atkinson J, Liminana P, Chillon JM. Captopril improves cerebrovascular structure and function in old hypertensive rats. Br J Pharmacol 144: 349–356, 2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Dupuis F, Atkinson J, Liminana P, Chillon JM. Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats. J Hypertens 23: 1061–1066, 2005. [DOI] [PubMed] [Google Scholar]
  • 61. Dupuis F, Vincent JM, Liminana P, Chillon JM, Capdeville-Atkinson C, Atkinson J. Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat. J Hypertens 28: 1566–1573, 2010. [DOI] [PubMed] [Google Scholar]
  • 62. Earley S. Endothelium-dependent cerebral artery dilation mediated by transient receptor potential and Ca2+-activated K+ channels. J Cardiovasc Pharmacol 57: 148–153, 2011. [DOI] [PubMed] [Google Scholar]
  • 63. Earley S, Brayden JE. Transient receptor potential channels and vascular function. Clin Sci (Lond) 119: 19–36, 2010. [DOI] [PubMed] [Google Scholar]
  • 64. Earley S, Heppner TJ, Nelson MT, Brayden JE. TRPV4 forms a novel Ca2+ signaling complex with ryanodine receptors and BKCa channels. Circ Res 97: 1270–1279, 2005. [DOI] [PubMed] [Google Scholar]
  • 65. Earley S, Pauyo T, Drapp R, Tavares MJ, Liedtke W, Brayden JE. TRPV4-dependent dilation of peripheral resistance arteries influences arterial pressure. Am J Physiol Heart Circ Physiol 297: H1096–H1102, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Ezan P, Andre P, Cisternino S, Saubamea B, Boulay AC, Doutremer S, Thomas MA, Quenech'du N, Giaume C, Cohen-Salmon M. Deletion of astroglial connexins weakens the blood-brain barrier. J Cereb Blood Flow Metab 32: 1457–1467, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol 300: H1566–H1582, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Faraci FM, Baumbach GL, Heistad DD. Myogenic mechanisms in the cerebral circulation. J Hypertens Suppl 7: S61–S64, 1989. [PubMed] [Google Scholar]
  • 69. Faraci FM, Brian JE., Jr Nitric oxide and the cerebral circulation. Stroke 25: 692–703, 1994. [DOI] [PubMed] [Google Scholar]
  • 70. Faraci FM, Heistad DD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res 66: 8–17, 1990. [DOI] [PubMed] [Google Scholar]
  • 71. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110: 1103–1107, 2004. [DOI] [PubMed] [Google Scholar]
  • 72. Folkow B, Hallback M, Lundgren Y, Sivertsson R, Weiss L. Importance of adaptive changes in vascular design for establishment of primary hypertension, studied in man and in spontaneously hypertensive rats. Circ Res 32, Suppl 1: 2–16, 1973. [DOI] [PubMed] [Google Scholar]
  • 73. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90: 251–262, 2002. [PubMed] [Google Scholar]
  • 74. Geary GG, Krause DN, Duckles SP. Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am J Physiol Heart Circ Physiol 279: H511–H519, 2000. [DOI] [PubMed] [Google Scholar]
  • 75. Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG, Narayanan J, Falck JR, Okamoto H, Roman RJ, Nithipatikom K, Campbell WB, Harder DR. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res 87: 60–65, 2000. [DOI] [PubMed] [Google Scholar]
  • 76. Giachini FR, Carneiro FS, Lima VV, Carneiro ZN, Dorrance A, Webb RC, Tostes RC. Upregulation of intermediate calcium-activated potassium channels counterbalance the impaired endothelium-dependent vasodilation in stroke-prone spontaneously hypertensive rats. Transl Res 154: 183–193, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 100: 328–335, 2006. [DOI] [PubMed] [Google Scholar]
  • 78. Gonzales RJ, Krause DN, Duckles SP. Testosterone suppresses endothelium-dependent dilation of rat middle cerebral arteries. Am J Physiol Heart Circ Physiol 286: H552–H560, 2004. [DOI] [PubMed] [Google Scholar]
  • 79. Griffin KA, Churchill PC, Picken M, Webb RC, Kurtz TW, Bidani AK. Differential salt-sensitivity in the pathogenesis of renal damage in SHR and stroke prone SHR. Am J Hypertens 14: 311–320, 2001. [DOI] [PubMed] [Google Scholar]
  • 80. Guan YY, Wang GL, Zhou JG. The ClC-3 Cl- channel in cell volume regulation, proliferation and apoptosis in vascular smooth muscle cells. Trends Pharmacol Sci 27: 290–296, 2006. [DOI] [PubMed] [Google Scholar]
  • 81. Hahn C, Schwartz MA. The role of cellular adaptation to mechanical forces in atherosclerosis. Arterioscler Thromb Vasc Biol 28: 2101–2107, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Hajdu MA, Heistad DD, Baumbach GL. Effects of antihypertensive therapy on mechanics of cerebral arterioles in rats. Hypertension 17: 308–316, 1991. [DOI] [PubMed] [Google Scholar]
  • 83. Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol 100: 1059–1064, 2006. [DOI] [PubMed] [Google Scholar]
  • 84. Hamner JW, Tan CO, Lee K, Cohen MA, Taylor JA. Sympathetic control of the cerebral vasculature in humans. Stroke 41: 102–109, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85. Hamner JW, Tan CO, Tzeng YC, Taylor JA. Cholinergic control of the cerebral vasculature in humans. J Physiol 590: 6343–6352, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Harder DR, Alkayed NJ, Lange AR, Gebremedhin D, Roman RJ. Functional hyperemia in the brain: hypothesis for astrocyte-derived vasodilator metabolites. Stroke 29: 229–234, 1998. [DOI] [PubMed] [Google Scholar]
  • 87. Harper SL, Bohlen HG. Microvascular adaptation in the cerebral cortex of adult spontaneously hypertensive rats. Hypertension 6: 408–419, 1984. [DOI] [PubMed] [Google Scholar]
  • 88. Hayashi K, Naiki T. Adaptation and remodeling of vascular wall; biomechanical response to hypertension. J Mech Behav Biomed Mater 2: 3–19, 2009. [DOI] [PubMed] [Google Scholar]
  • 89. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 21: 391–397, 1993. [DOI] [PubMed] [Google Scholar]
  • 90. Heistad DD, Baumbach GL. Cerebral vascular changes during chronic hypertension: good guys and bad guys. J Hypertens Suppl 10: S71–S75, 1992. [PubMed] [Google Scholar]
  • 91. Heistad DD, Mayhan WG, Coyle P, Baumbach GL. Impaired dilatation of cerebral arterioles in chronic hypertension. Blood Vessels 27: 258–262, 1990. [DOI] [PubMed] [Google Scholar]
  • 92. Hogestatt ED, Andersson KE. On the postjunctional alpha-adrenoreceptors in rat cerebral and mesenteric arteries. J Auton Pharmacol 4: 161–173, 1984. [DOI] [PubMed] [Google Scholar]
  • 93. Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz MA. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-l-arginine. J Cereb Blood Flow Metab 16: 981–987, 1996. [DOI] [PubMed] [Google Scholar]
  • 94. Hwang J, Ing MH, Salazar A, Lassegue B, Griendling K, Navab M, Sevanian A, Hsiai TK. Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: implication for native LDL oxidation. Circ Res 93: 1225–1232, 2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab 7: 476–484, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96. Ibrahim J, McGee A, Graham D, McGrath JC, Dominiczak AF. Sex-specific differences in cerebral arterial myogenic tone in hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol 290: H1081–H1089, 2006. [DOI] [PubMed] [Google Scholar]
  • 97. Iliff JJ, Wang R, Zeldin DC, Alkayed NJ. Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels. Am J Physiol Heart Circ Physiol 296: H1352–H1363, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39: 690–694, 2002. [DOI] [PubMed] [Google Scholar]
  • 99. Inoue R, Jensen LJ, Shi J, Morita H, Nishida M, Honda A, Ito Y. Transient receptor potential channels in cardiovascular function and disease. Circ Res 99: 119–131, 2006. [DOI] [PubMed] [Google Scholar]
  • 100. Ishizuka T, Niwa A, Tabuchi M, Nagatani Y, Ooshima K, Higashino H. Involvement of thromboxane A2 receptor in the cerebrovascular damage of salt-loaded, stroke-prone rats. J Hypertens 25: 861–870, 2007. [DOI] [PubMed] [Google Scholar]
  • 101. Izzard AS, Graham D, Burnham MP, Heerkens EH, Dominiczak AF, Heagerty AM. Myogenic and structural properties of cerebral arteries from the stroke-prone spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 285: H1489–H1494, 2003. [DOI] [PubMed] [Google Scholar]
  • 102. Izzard AS, Rizzoni D, Agabiti-Rosei E, Heagerty AM. Small artery structure and hypertension: adaptive changes and target organ damage. J Hypertens 23: 247–250, 2005. [DOI] [PubMed] [Google Scholar]
  • 103. Jarajapu YP, Knot HJ. Relative contribution of Rho kinase and protein kinase C to myogenic tone in rat cerebral arteries in hypertension. Am J Physiol Heart Circ Physiol 289: H1917–H1922, 2005. [DOI] [PubMed] [Google Scholar]
  • 104. Jennings JR, Muldoon MF, Ryan C, Price JC, Greer P, Sutton-Tyrrell K, van der Veen FM, Meltzer CC. Reduced cerebral blood flow response and compensation among patients with untreated hypertension. Neurology 64: 1358–1365, 2005. [DOI] [PubMed] [Google Scholar]
  • 105. Jimenez-Altayo F, Martin A, Rojas S, Justicia C, Briones AM, Giraldo J, Planas AM, Vila E. Transient middle cerebral artery occlusion causes different structural, mechanical, and myogenic alterations in normotensive and hypertensive rats. Am J Physiol Heart Circ Physiol 293: H628–H635, 2007. [DOI] [PubMed] [Google Scholar]
  • 106. Jones SC, Radinsky CR, Furlan AJ, Chyatte D, Perez-Trepichio AD. Cortical NOS inhibition raises the lower limit of cerebral blood flow-arterial pressure autoregulation. Am J Physiol Heart Circ Physiol 276: H1253–H1262, 1999. [DOI] [PubMed] [Google Scholar]
  • 107. Joutel A, Monet-Lepretre M, Gosele C, Baron-Menguy C, Hammes A, Schmidt S, Lemaire-Carrette B, Domenga V, Schedl A, Lacombe P, Hubner N. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest 120: 433–445, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Kahles T, Luedike P, Endres M, Galla HJ, Steinmetz H, Busse R, Neumann-Haefelin T, Brandes RP. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 38: 3000–3006, 2007. [DOI] [PubMed] [Google Scholar]
  • 109. Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. Neurol Clin 25: 577–609, 2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110. Kengne AP, Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Gu DF, Suh I, Woodward M. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens 25: 1205–1213, 2007. [DOI] [PubMed] [Google Scholar]
  • 111. Kety SS, Hafkenschiel JH, Jeffers WA, Leopold IH, Shenkin HA. The blood flow, vascular resistance, and oxygen consumption of the brain in essential hypertension. J Clin Invest 27: 511–514, 1948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112. Kevil CG, Oshima T, Alexander B, Coe LL, Alexander JS. H2O2-mediated permeability: role of MAPK and occludin. Am J Physiol Cell Physiol 279: C21–C30, 2000. [DOI] [PubMed] [Google Scholar]
  • 113. Kim KJ, Filosa JA. Advanced in vitro approach to study neurovascular coupling mechanisms in the brain microcirculation. J Physiol 590: 1757–1770, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114. Kimura S, Saito H, Minami M, Togashi H, Nakamura N, Nemoto M, Parvez HS. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 153: 167–178, 2000. [DOI] [PubMed] [Google Scholar]
  • 115. Koller A, Toth P. Contribution of flow-dependent vasomotor mechanisms to the autoregulation of cerebral blood flow. J Vasc Res 49: 375–389, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Kumai Y, Ooboshi H, Ago T, Ishikawa E, Takada J, Kamouchi M, Kitazono T, Ibayashi S, Iida M. Protective effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressure. Exp Neurol 210: 441–448, 2008. [DOI] [PubMed] [Google Scholar]
  • 117. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 45: 1050–1055, 2005. [DOI] [PubMed] [Google Scholar]
  • 118. Ledingham JM, Laverty R. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model. Clin Exp Pharmacol Physiol 32: 76–85, 2005. [DOI] [PubMed] [Google Scholar]
  • 119. Ledingham JM, Laverty R. Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats. Clin Exp Pharmacol Physiol 32: 919–925, 2005. [DOI] [PubMed] [Google Scholar]
  • 120. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913, 2002. [DOI] [PubMed] [Google Scholar]
  • 121. Lincoln J. Innervation of cerebral arteries by nerves containing 5-hydroxytryptamine and noradrenaline. Pharmacol Ther 68: 473–501, 1995. [DOI] [PubMed] [Google Scholar]
  • 122. Lindauer U, Megow D, Matsuda H, Dirnagl U. Nitric oxide: a modulator, but not a mediator, of neurovascular coupling in rat somatosensory cortex. Am J Physiol Heart Circ Physiol 277: H799–H811, 1999. [DOI] [PubMed] [Google Scholar]
  • 123. Liu S, Agalliu D, Yu C, Fisher M. The role of pericytes in blood-brain barrier function and stroke. Curr Pharm Des 18: 3653–3662, 2012. [DOI] [PubMed] [Google Scholar]
  • 124. Liu X, Li C, Falck JR, Roman RJ, Harder DR, Koehler RC. Interaction of nitric oxide, 20-HETE, and EETs during functional hyperemia in whisker barrel cortex. Am J Physiol Heart Circ Physiol 295: H619–H631, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125. Liu YJ, Wang XG, Tang YB, Chen JH, Lv XF, Zhou JG, Guan YY. Simvastatin ameliorates rat cerebrovascular remodeling during hypertension via inhibition of volume-regulated chloride channel. Hypertension 56: 445–452, 2010. [DOI] [PubMed] [Google Scholar]
  • 126. Lochhead JJ, McCaffrey G, Sanchez-Covarrubias L, Finch JD, Demarco KM, Quigley CE, Davis TP, Ronaldson PT. Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain. Am J Physiol Heart Circ Physiol 302: H582–H593, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127. Maeda K, Hata R, Bader M, Walther T, Hossmann KA. Larger anastomoses in angiotensinogen-knockout mice attenuate early metabolic disturbances after middle cerebral artery occlusion. J Cereb Blood Flow Metab 19: 1092–1098, 1999. [DOI] [PubMed] [Google Scholar]
  • 128. Malomvolgyi B, Hadhazy P, Magyar K, Kanai K, Simonidesz V. Relaxation by prostacyclin (PGI2) and 7-oxo-PGI2 of isolated cerebral, coronary and mesenteric arteries. Acta Physiol Acad Sci Hung 60: 251–256, 1982. [PubMed] [Google Scholar]
  • 129. Mangat HS. Severe traumatic brain injury. Continuum (Minneap Minn) 18: 532–546, 2012. [DOI] [PubMed] [Google Scholar]
  • 130. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 297: F740–F748, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131. Marrelli SP, Eckmann MS, Hunte MS. Role of endothelial intermediate conductance KCa channels in cerebral EDHF-mediated dilations. Am J Physiol Heart Circ Physiol 285: H1590–H1599, 2003. [DOI] [PubMed] [Google Scholar]
  • 132. Martinez-Lemus LA, Zhao G, Galinanes EL, Boone M. Inward remodeling of resistance arteries requires reactive oxygen species-dependent activation of matrix metalloproteinases. Am J Physiol Heart Circ Physiol 300: H2005–H2015, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133. Martinez-Revelles S, Jimenez-Altayo F, Caracuel L, Perez-Asensio FJ, Planas AM, Vila E. Endothelial dysfunction in rat mesenteric resistance artery after transient middle cerebral artery occlusion. J Pharmacol Exp Ther 325: 363–369, 2008. [DOI] [PubMed] [Google Scholar]
  • 134. Mayhan WG, Amundsen SM, Faraci FM, Heistad DD. Responses of cerebral arteries after ischemia and reperfusion in cats. Am J Physiol Heart Circ Physiol 255: H879–H884, 1988. [DOI] [PubMed] [Google Scholar]
  • 135. Mayhan WG, Faraci FM, Heistad DD. Disruption of the blood-brain barrier in cerebrum and brain stem during acute hypertension. Am J Physiol Heart Circ Physiol 251: H1171–H1175, 1986. [DOI] [PubMed] [Google Scholar]
  • 136. Meyer JS, Rauch G, Rauch RA, Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol Aging 21: 161–169, 2000. [DOI] [PubMed] [Google Scholar]
  • 137. Miller AA, Budzyn K, Sobey CG. Vascular dysfunction in cerebrovascular disease: mechanisms and therapeutic intervention. Clin Sci (Lond) 119: 1–17, 2010. [DOI] [PubMed] [Google Scholar]
  • 138. Miller AA, Drummond GR, Schmidt HH, Sobey CG. NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res 97: 1055–1062, 2005. [DOI] [PubMed] [Google Scholar]
  • 139. Moody DM, Bell MA, Challa VR. Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. AJNR Am J Neuroradiol 11: 431–439, 1990. [PMC free article] [PubMed] [Google Scholar]
  • 140. Moreau P, Takase H, Kung CF, van Rooijen MM, Schaffner T, Luscher TF. Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition. Stroke 26: 1922–1928, 1995. [DOI] [PubMed] [Google Scholar]
  • 141. Mueller SM, Heistad DD. Effect of chronic hypertension on the blood-brain barrier. Hypertension 2: 809–812, 1980. [DOI] [PubMed] [Google Scholar]
  • 142. Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings MI. Hypertension and longitudinal changes in cerebral blood flow: The SMART-MR study. Ann Neurol 71: 825–833 2012. [DOI] [PubMed] [Google Scholar]
  • 143. Mulvany MJ. Small artery remodeling and significance in the development of hypertension. News Physiol Sci 17: 105–109, 2002. [DOI] [PubMed] [Google Scholar]
  • 144. Mulvany MJ. Small artery remodelling in hypertension. Basic Clin Pharmacol Toxicol 110: 49–55, 2012. [DOI] [PubMed] [Google Scholar]
  • 145. Mulvany MJ, Aalkjaer C, Christensen J. Changes in noradrenaline sensitivity and morphology of arterial resistance vessels during development of high blood pressure in spontaneously hypertensive rats. Hypertension 2: 664–671, 1980. [DOI] [PubMed] [Google Scholar]
  • 146. Mulvany MJ, Baumbach GL, Aalkjaer C, Heagerty AM, Korsgaard N, Schiffrin EL, Heistad DD. Vascular remodeling. Hypertension 28: 505–506, 1996. [PubMed] [Google Scholar]
  • 147. Mulvany MJ, Hansen OK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res 43: 854–864, 1978. [DOI] [PubMed] [Google Scholar]
  • 148. Nag S. Immunohistochemical localization of extracellular matrix proteins in cerebral vessels in chronic hypertension. J Neuropathol Exp Neurol 55: 381–388, 1996. [DOI] [PubMed] [Google Scholar]
  • 149. Nag S, Kapadia A, Stewart DJ. Review: molecular pathogenesis of blood-brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol 37: 3–23, 2011. [DOI] [PubMed] [Google Scholar]
  • 150. Nag S, Kilty DW. Cerebrovascular changes in chronic hypertension. Protective effects of enalapril in rats. Stroke 28: 1028–1034, 1997. [DOI] [PubMed] [Google Scholar]
  • 151. Nelson MT, Conway MA, Knot HJ, Brayden JE. Chloride channel blockers inhibit myogenic tone in rat cerebral arteries. J Physiol 502: 259–264, 1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152. Nishimura N, Schaffer CB, Friedman B, Lyden PD, Kleinfeld D. Penetrating arterioles are a bottleneck in the perfusion of neocortex. Proc Natl Acad Sci USA 104: 365–370, 2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153. Niwa K, Araki E, Morham SG, Ross ME, Iadecola C. Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J Neurosci 20: 763–770, 2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154. Noorani MM, Noel RC, Marrelli SP. Upregulated TRPC3 and downregulated TRPC1 channel expression during hypertension is associated with increased vascular contractility in rat. Front Physiol 2: 42, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 155. Omote Y, Deguchi K, Tian F, Kawai H, Kurata T, Yamashita T, Ohta Y, Abe K. Clinical and pathological improvement in stroke-prone spontaneous hypertensive rats related to the pleiotropic effect of cilostazol. Stroke 43: 1639–1646, 2012. [DOI] [PubMed] [Google Scholar]
  • 156. Osmond JM, Dorrance AM. 11beta-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia. Endocrinology 150: 713–719, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157. Osmond JM, Mintz JD, Dalton B, Stepp DW. Obesity increases blood pressure, cerebral vascular remodeling, and severity of stroke in the Zucker rat. Hypertension 53: 381–386, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158. Osol G, Brekke JF, McElroy-Yaggy K, Gokina NI. Myogenic tone, reactivity, and forced dilatation: a three-phase model of in vitro arterial myogenic behavior. Am J Physiol Heart Circ Physiol 283: H2260–H2267, 2002. [DOI] [PubMed] [Google Scholar]
  • 159. Osol G, Halpern W. Myogenic properties of cerebral blood vessels from normotensive and hypertensive rats. Am J Physiol Heart Circ Physiol 249: H914–H921, 1985. [DOI] [PubMed] [Google Scholar]
  • 160. Oyama N, Yagita Y, Kawamura M, Sugiyama Y, Terasaki Y, Omura-Matsuoka E, Sasaki T, Kitagawa K. Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke 42: 2571–2577, 2011. [DOI] [PubMed] [Google Scholar]
  • 161. Oztas B, Kaya M. The effect of acute hypertension on blood-brain barrier permeability to albumin during experimentally induced epileptic seizures. Pharmacol Res 23: 41–46, 1991. [DOI] [PubMed] [Google Scholar]
  • 162. Paiardi S, Rodella LF, De Ciuceis C, Porteri E, Boari GE, Rezzani R, Rizzardi N, Platto C, Tiberio GA, Giulini SM, Rizzoni D, Agabiti-Rosei E. Immunohistochemical evaluation of microvascular rarefaction in hypertensive humans and in spontaneously hypertensive rats. Clin Hemorheol Microcirc 42: 259–268, 2009. [DOI] [PubMed] [Google Scholar]
  • 163. Paravicini TM, Drummond GR, Sobey CG. Reactive oxygen species in the cerebral circulation: physiological roles and therapeutic implications for hypertension and stroke. Drugs 64: 2143–2157, 2004. [DOI] [PubMed] [Google Scholar]
  • 164. Paravicini TM, Sobey CG. Cerebral vascular effects of reactive oxygen species: recent evidence for a role of NADPH-oxidase. Clin Exp Pharmacol Physiol 30: 855–859, 2003. [DOI] [PubMed] [Google Scholar]
  • 165. Park JB, Touyz RM, Chen X, Schiffrin EL. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens 15: 78–84, 2002. [DOI] [PubMed] [Google Scholar]
  • 166. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev 2: 161–192, 1990. [PubMed] [Google Scholar]
  • 167. Pires PW, Deutsch C, McClain JL, Rogers CT, Dorrance AM. Tempol, a superoxide dismutase mimetic, prevents cerebral vessel remodeling in hypertensive rats. Microvasc Res 80: 445–452, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168. Pires PW, Rogers CT, McClain JL, Garver HS, Fink GD, Dorrance AM. Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 301: H87–H97, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169. Potier M, Gonzalez JC, Motiani RK, Abdullaev IF, Bisaillon JM, Singer HA, Trebak M. Evidence for STIM1- and Orai1-dependent store-operated calcium influx through ICRAC in vascular smooth muscle cells: role in proliferation and migration. FASEB J 23: 2425–2437, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170. Qin X, Hurn PD, Littleton-Kearney MT. Estrogen restores postischemic sensitivity to the thromboxane mimetic U46619 in rat pial artery. J Cereb Blood Flow Metab 25: 1041–1046, 2005. [DOI] [PubMed] [Google Scholar]
  • 171. Queisser N, Fazeli G, Schupp N. Superoxide anion and hydrogen peroxide-induced signaling and damage in angiotensin II and aldosterone action. Biol Chem 391: 1265–1279, 2010. [DOI] [PubMed] [Google Scholar]
  • 172. Reading SA, Earley S, Waldron BJ, Welsh DG, Brayden JE. TRPC3 mediates pyrimidine receptor-induced depolarization of cerebral arteries. Am J Physiol Heart Circ Physiol 288: H2055–H2061, 2005. [DOI] [PubMed] [Google Scholar]
  • 173. Rigsby CS, Ergul A, Portik Dobos V, Pollock DM, Dorrance AM. Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension. Am J Hypertens 24: 708–715, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174. Rigsby CS, Pollock DM, Dorrance AM. Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvasc Res 73: 198–205, 2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 175. Roggendorf W, Cervos-Navarro J. Ultrastructure of arterioles in the cat brain. Cell Tissue Res 178: 495–515, 1977. [DOI] [PubMed] [Google Scholar]
  • 176. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131–185, 2002. [DOI] [PubMed] [Google Scholar]
  • 177. Rosenblum WI, Wormley B. Selective depression of endothelium-dependent dilations during cerebral ischemia. Stroke 26: 1877–1881, 1995. [DOI] [PubMed] [Google Scholar]
  • 178. Sa-Pereira I, Brites D, Brito MA. Neurovascular unit: a focus on pericytes. Mol Neurobiol 45: 327–347, 2012. [DOI] [PubMed] [Google Scholar]
  • 179. Schmid-Schonbein GW, Seiffge D, DeLano FA, Shen K, Zweifach BW. Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension 17: 323–330, 1991. [DOI] [PubMed] [Google Scholar]
  • 180. Shi XL, Wang GL, Zhang Z, Liu YJ, Chen JH, Zhou JG, Qiu QY, Guan YY. Alteration of volume-regulated chloride movement in rat cerebrovascular smooth muscle cells during hypertension. Hypertension 49: 1371–1377, 2007. [DOI] [PubMed] [Google Scholar]
  • 181. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9: 959–968, 2010. [DOI] [PubMed] [Google Scholar]
  • 182. Si H, Heyken WT, Wolfle SE, Tysiac M, Schubert R, Grgic I, Vilianovich L, Giebing G, Maier T, Gross V, Bader M, de Wit C, Hoyer J, Kohler R. Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res 99: 537–544, 2006. [DOI] [PubMed] [Google Scholar]
  • 183. Sierra C, Domenech M, Camafort M, Coca A. Hypertension and mild cognitive impairment. Curr Hypertens Rep 14: 548–555, 2012. [DOI] [PubMed] [Google Scholar]
  • 184. Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 174: 2086–2095, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 185. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 28: 605–611, 2006. [DOI] [PubMed] [Google Scholar]
  • 186. Smeda JS, VanVliet BN, King SR. Stroke-prone spontaneously hypertensive rats lose their ability to auto-regulate cerebral blood flow prior to stroke. J Hypertens 17: 1697–1705, 1999. [DOI] [PubMed] [Google Scholar]
  • 187. Sobey CG, Heistad DD, Faraci FM. Mechanisms of bradykinin-induced cerebral vasodilatation in rats. Evidence that reactive oxygen species activate K+ channels. Stroke 28: 2290–2294, 1997. [DOI] [PubMed] [Google Scholar]
  • 188. Sokolova IA, Manukhina EB, Blinkov SM, Koshelev VB, Pinelis VG, Rodionov IM. Rarefication of the arterioles and capillary network in the brain of rats with different forms of hypertension. Microvasc Res 30: 1–9, 1985. [DOI] [PubMed] [Google Scholar]
  • 189. Sonkusare SK, Bonev AD, Ledoux J, Liedtke W, Kotlikoff MI, Heppner TJ, Hill-Eubanks DC, Nelson MT. Elementary Ca2+ signals through endothelial TRPV4 channels regulate vascular function. Science 336: 597–601, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 190. Sporkova A, Kopkan L, Varcabova S, Huskova Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Cervenka L. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. Am J Physiol Regul Integr Comp Physiol 300: R1468–R1475, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 191. Stankevicius E, Dalsgaard T, Kroigaard C, Beck L, Boedtkjer E, Misfeldt MW, Nielsen G, Schjorring O, Hughes A, Simonsen U. Opening of small and intermediate calcium-activated potassium channels induces relaxation mainly mediated by nitric-oxide release in large arteries and endothelium-derived hyperpolarizing factor in small arteries from rat. J Pharmacol Exp Ther 339: 842–850, 2011. [DOI] [PubMed] [Google Scholar]
  • 192. Strange K. Cellular volume homeostasis. Adv Physiol Educ 28: 155–159, 2004. [DOI] [PubMed] [Google Scholar]
  • 193. Sugamura K, Keaney JF., Jr Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 51: 978–992, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 194. Suzuki K, Masawa N, Sakata N, Takatama M. Pathologic evidence of microvascular rarefaction in the brain of renal hypertensive rats. J Stroke Cerebrovasc Dis 12: 8–16, 2003. [DOI] [PubMed] [Google Scholar]
  • 195. Talman WT, Nitschke Dragon D. Neuronal nitric oxide mediates cerebral vasodilatation during acute hypertension. Brain Res 1139: 126–132, 2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 196. Tamaki K, Sadoshima S, Baumbach GL, Iadecola C, Reis DJ, Heistad DD. Evidence that disruption of the blood-brain barrier precedes reduction in cerebral blood flow in hypertensive encephalopathy. Hypertension 6: I75–I81, 1984. [DOI] [PubMed] [Google Scholar]
  • 197. Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res 34: 5–14, 2011. [DOI] [PubMed] [Google Scholar]
  • 198. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 30: 860–866, 2003. [DOI] [PubMed] [Google Scholar]
  • 199. Traub O, Lloyd MC, Webb RC. Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats. Cardiovasc Drugs Ther 9: 421–429, 1995. [DOI] [PubMed] [Google Scholar]
  • 200. Usatyuk PV, Natarajan V. Regulation of reactive oxygen species-induced endothelial cell-cell and cell-matrix contacts by focal adhesion kinase and adherens junction proteins. Am J Physiol Lung Cell Mol Physiol 289: L999–L1010, 2005. [DOI] [PubMed] [Google Scholar]
  • 201. Vacher E, Richer C, Giudicelli JF. Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. J Hypertens 14: 1341–1348, 1996. [DOI] [PubMed] [Google Scholar]
  • 202. Vandenhaute E, Culot M, Gosselet F, Dehouck L, Godfraind C, Franck M, Plouet J, Cecchelli R, Dehouck MP, Ruchoux MM. Brain pericytes from stress-susceptible pigs increase blood-brain barrier permeability in vitro. Fluids Barriers CNS 9: 11, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 203. Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem 76: 387–417, 2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 204. Vorstrup S, Barry DI, Jarden JO, Svendsen UG, Braendstrup O, Graham DI, Strandgaard S. Chronic antihypertensive treatment in the rat reverses hypertension-induced changes in cerebral blood flow autoregulation. Stroke 15: 312–318, 1984. [DOI] [PubMed] [Google Scholar]
  • 205. Vriens J, Owsianik G, Fisslthaler B, Suzuki M, Janssens A, Voets T, Morisseau C, Hammock BD, Fleming I, Busse R, Nilius B. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 97: 908–915, 2005. [DOI] [PubMed] [Google Scholar]
  • 206. Wang M, Yang H, Zheng LY, Zhang Z, Tang YB, Wang GL, Du YH, Lv XF, Liu J, Zhou JG, Guan YY. Downregulation of TMEM16A calcium-activated chloride channel contributes to cerebrovascular remodeling during hypertension by promoting basilar smooth muscle cell proliferation. Circulation 125: 697–707, 2012. [DOI] [PubMed] [Google Scholar]
  • 207. Watanabe Y, Littleton-Kearney MT, Traystman RJ, Hurn PD. Estrogen restores postischemic pial microvascular dilation. Am J Physiol Heart Circ Physiol 281: H155–H160, 2001. [DOI] [PubMed] [Google Scholar]
  • 208. Werber AH, Fitch-Burke MC, Harrington DG, Shah J. No rarefaction of cerebral arterioles in hypertensive rats. Can J Physiol Pharmacol 68: 476–479, 1990. [DOI] [PubMed] [Google Scholar]
  • 209. Wu MH. Endothelial focal adhesions and barrier function. J Physiol 569: 359–366, 2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 210. Xi Q, Cheranov SY, Jaggar JH. Mitochondria-derived reactive oxygen species dilate cerebral arteries by activating Ca2+ sparks. Circ Res 97: 354–362, 2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 211. Xie MJ, Zhang LF, Ma J, Cheng HW. Functional alterations in cerebrovascular K+ and Ca2+ channels are comparable between simulated microgravity rat and SHR. Am J Physiol Heart Circ Physiol 289: H1265–H1276, 2005. [DOI] [PubMed] [Google Scholar]
  • 212. Yamakawa H, Jezova M, Ando H, Saavedra JM. Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition. J Cereb Blood Flow Metab 23: 371–380, 2003. [DOI] [PubMed] [Google Scholar]
  • 213. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke 37: 1087–1093, 2006. [DOI] [PubMed] [Google Scholar]
  • 214. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059–36062, 2001. [DOI] [PubMed] [Google Scholar]
  • 215. Zhang J, Friedman MH. Adaptive response of vascular endothelial cells to an acute increase in shear stress magnitude. Am J Physiol Heart Circ Physiol 302: H983–H991, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 216. Zhou JG, Ren JL, Qiu QY, He H, Guan YY. Regulation of intracellular Cl concentration through volume-regulated ClC-3 chloride channels in A10 vascular smooth muscle cells. J Biol Chem 280: 7301–7308, 2005. [DOI] [PubMed] [Google Scholar]
  • 217. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178–201, 2008. [DOI] [PubMed] [Google Scholar]
  • 218. Zubcevic J, Waki H, Raizada MK, Paton JF. Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension 57: 1026–1033. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Physiology - Heart and Circulatory Physiology are provided here courtesy of American Physiological Society

RESOURCES